Clinical Study Protocol (CSP), ANGEL
Version 17.  0
Template Form Doc ID: LDMS_001_00026737
Parent Doc ID: SOP AZDoc0018580This submission document contains confidential commercial information, disclosure of which is prohibited 
without providing advance notice to AZ and opportunity to object.  
This Clinical Study Protocol has been subject to a peer review according to AZ Sta ndard procedures.  The 
clinical study protocol is publicly registered and the results are disclosed and/or published according to the AZ 
Global Policy on Bioethics and in compliance with prevailing laws and regulations.  Clinical Study Protocol 
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17March 2020 
A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and 
Cardiovascular Mortality in Patients with Chronic Kidney Disease
Sponsor: AZ AB, 151 85 Södertälje, Sweden
Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
3 (98)5.1.1 Endpoint reporting overview
5.1.3 Potential renal endpointsRemoving the requirement of adjudicating potential endpoints 
related to estimated glomerular filtration rate (eGFR) decline.  
The r ational for th is change is that the endpoint criteria are not 
justifying adjudication of these events. 
6.3 Recording of adverse events
6.3.2.2 Renal eventsClarification added based on feedback that the criteria was too 
vague, regarding what is considere d an adverse e vent (AE) of 
interest in terms renal events. 
6.3 Recording of adverse events
6.3.7 Adverse events based on 
examination and testsLimiting the recording of AEs to not include potential renal 
endpoints that are based on examination and tests, i.e., 
laborat ory results only, unless fulfilling the serious adverse 
event (SAE) criteria or Discontinuation of investigational 
product due to adverse event (DAE) criteria. The reason not to 
record these endpoints related to laboratory findings is that 
protocol mandate d laboratory values will be systematically 
analysed.  
6.4.1 Reporting of SAEs 
considered to be potential 
endpointsLimiting the event types that are being withheld from reporting 
to health authorities to include only heart failure endpoints and 
fatal AE. i.e., AEs related to renal endpoints will not be 
withheld. The rationale for this limitation is to simplify the SAE 
reporting and to minimise the risk for withholding renal AEs of 
interest, which should be reported, and which could be confus ed 
for being a primary or secondary renal endpoint. 
6.9 Medication Error Adding information about Medication Error definition and 
reporting.
7.7.2 Prohibited medication Clarifying that open label treatment with Sodium glucose co -
transporter 2 (SGLT2) in combination w ith IP is not allowed and 
that open label treatment with SGLT2 inhibitors should be 
avoided during the course of the study, i.e., clarifying that usage 
of open label treatment with SGLT2 inhibitors are not prohibited 
if the patient is not tak ing study medi cation but should be 
avoided. The rational for this update is to clarify that it is 
administration of an open label SGLT2 inhibition in 
combination with IP that is a protocol deviation and not if the 
patient is off IP. 
7.7.3 Recording of co ncomitant 
medi cationIncluding cardiovascular (CV) medications to be recorded in 
detail in the electronic case report form (eCRF) during the 
course of the study.
Clinical Study Protocol (CSP), ANGEL
Version 17.  0
Template Form Doc ID: LDMS_001_00026737
Parent Doc ID: SOP AZDoc0018580PROTOCOL SYNOPSIS
A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and 
Cardiovascular Mortality in Patients with Chronic Kidney Disease
International Coordinating Investigator
Prof. , MB ChB, MD, FRCP
Centre for Nephrology  Roy al Free Campus 
Universit y Co llege London
London, United Kingdo m
Scientific Coordinator
Prof. , PharmD, PhD, 
Dept. Clinical Pharmacy  & Pharm acology
Universit y Medical Center Groningen , 
Groningen, Netherlands
Study site(s) and number of patients planned
Study period Phase of development
Estimated date of first patient enroll ed Q12017 Phase III
Estimated date of last patient completed Q42020
Study design
This is an international , mul ticentre, event -driven, rando mised, double -blind, parallel group, 
placebo -controlled study , evaluat ing the effect of dapagliflozin 10 mg ver sus pl acebo, given 
once daily  in addi tion to standard of care, to prevent the progression of chronic kidney dis ease 
(CKD) or cardiovascular (CV)/renal death.

Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
7 (98)Objectives
Primary Objective: Outcome Measure:
To determine if dapagliflozin is superior to 
placebo in reducing the incidence of the primary 
composite endpoint of ≥50% sustained decline in 
estimated glomerul ar fil tration rate (eGFR), 
reaching end stage renal disease (ESRD), CV or 
renal death when added to current background 
therapy in patients with e GFR ≥25 and 
≤75mL/min/1.73m2and albuminuria (urine 
albumin creatinine ratio [UACR] ≥200 and 
≤5000 mg/g).Time to the first occurrence of any of the 
components of this composite: 
1. ≥50% sustained* decline in eGFR 
2. Reaching ESRD 
Sustained* eGFR 
<15mL/min/1.73m2or, 
Chronic* dialysis treatment or,
Receiving a renal transplant
3. CV death 
4. Renal death
*As defined in t he Cli nical Event Adjudication (CEA) charter
Secondary Objective: Outcome Measure:
To determine whether dapagliflozin compared 
with placebo will result in a reduction of the 
incidence of the composite endpoints of 
worsening of renal function.  Time to the fi rst occurrence of any of the 
components of this composite: 
1. ≥50% sustained decline in eGFR
2. Reaching ESRD
3. Renal death
To determine whether dapagliflozin compared 
with placebo will result in a reduction of the 
incidence of the composite endpoint of CV death 
or hospitalisation for heart failure.  Time to the first o ccurrence of either of the 
components of this composite: 
1. CV death 
2. Hospitalisation for heart failure 
To determine whether dapagliflozin compared 
with placebo will result in a reduction of the 
incidence of all -cause mortality.  Time to death from any ca use
Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
8 (98)Safety Objective: Outcome Measure:
To evaluate the safety and tolerability of 
dapagliflozin in this patient population.  1. S erious adverse event (SAE)
2. Discontinuation of investigational 
product (IP) due to adverse event 
(DAE)s
3. Changes in clinical 
chemistry /haematology parameters
4. Adverse events (AEs) of interest 
(volume depletion, renal events, major 
hypoglycaemic events, fractures, 
diabetic ketoacidosis (DKA), Adverse 
events (AEs) leading to amputation 
and AEs leading to a risk for lower 
limb amputati ons [“preceding 
events”])
Target patient population
Thetarget popul ation will  have CKD (eGFR ≥25 and ≤75 mL/min/1.73m2) with albuminuria 
(urine albumin creat inine ratio [UACR] ≥200 and ≤5000 mg/g) with or without ty pe 2 
diabetes (T2D).  However, patients with known polycyst ic kidney disease, glo merulonephrit is 
with flares (lupus or anti -neutrophil cytoplasmic ant ibodies (ANCA) associated vasculit is) or 
ongoing act ive renal inflammat ion will be excluded.
Duration of treatment
This study  is event -driven.  The anticipated duration of the study  is approximately  45months 
with an estimated m ean treatm ent peri od for a patient of 33 months.  The study  closure 
procedures will be init iated when the predetermined number of primary endpo ints are 
predi cted to have occurred (n=681), i.e., the study  end date (SED).  The stud y durati on may  be 
changed if the event rate or randomisat ion rate i s different than ant icipated.  The study  may be 
terminated early if eit her a clear beneficial or harmful effect of the study  treatm ent is detected 
during the Data Monitoring Co mmittee (DMC) review.  
Investigational product (IP) , dosage and mode of administration
Patients will  be randomised 1:1 to either dapagliflo zin 10 m g or pl acebo.  Every  attem pt 
shoul d be made to m aintain pat ients on dapagliflozin 10 mg or matching placebo during the 
course of the study .  In addi tion to the preferred 10 mg dose, the 5 mg dose of dapagliflozin 
Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
9 (98)can be used in the study  when clinically indicated.  If the dose has been decreased to 5 mg, the 
dose should be increased back to dapagliflozin 10 mg or matching pl acebo as soon as, in the 
opinio n of the invest igator, the patient’s condit ion is stable.
Statistical methods
The primary  object ive of the study  is to determine the superiorit y of dapagliflo zin versus 
placebo in reducing the incidence of the primary  com posite endpoint.  Assuming a true hazard 
ratio of 0.78 between dapagliflozin and placebo, using a one -sided alpha of 2.5%, 681 primary  
endpo int events will provide a statistical power of 90% for the test of the primary  com posite 
endpo int.  Thi s is based on an overall 1:1 allocat ion between dapagliflozin and placebo.  The 
study  is event -driven.
With an annual event rate of 7.5% in the placebo treatment group, 4000 patients are estimated 
to provi de the requi red number of primary  events, based on an anticipated re cruitment period 
of 24 m onths and an average fo llow-up peri od of  approximately  33 m onths.
All patients who have been randomised to study  treatm ent will be included in the full analysis 
set (FAS) irrespect ive of their protocol adherence and cont inued partic ipation in the study .  
The primary  variable is the time to first event included in the primary  com posite endpoint.  
The primary  analysis will be based on the intent ion to treat (ITT) principle using the FAS.  In 
the analysis o f the primary co mposite endpo int, dapagliflo zin versus placebo will be compared 
using a Cox proportional hazards model with a factor for treatment group, stratified by 
rando misat ion stratificat ion factors (T2D, UACR), and adjusting for eGFR.  
A closed testing procedure including a pre -specified hierarchical ordering of the primary  and 
secondary  endpoints will  be utilized.  No m ultiplicity control  is placed on the exploratory  
endpo ints.
Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
10 (98)TABLE OF CONTENTS PAGE
TITLE PAGE ....................................................................................................... 1
VERSION HISTORY .......................................................................................... 2
PROTOCOL SYNOPSIS ..................................................................................... 6
TABLE OF CONTENTS ................................................................................... 10
1. INTRODUCTION ............................................................................................. 19
1.1 Background and rationale for conducting this study ........................................... 19
1.2 Rationale for study  design, doses and control groups .......................................... 20
1.2.1 Rationale for study  design and study  popul ation................................................. 20
1.2.2 Rationale for primary outcome measure ............................................................. 21
1.2.3 Rationale for secondary  outcom e measure .......................................................... 21
1.2.4 Rationale for dose sel ection................................................................................ 21
1.3 Benefit/risk and ethical assessment .................................................................... 22
1.3.1 Potenti al risks.................................................................................................... 22
1.3.1.1 Protecti on against ri sks................................
...................................................... 23
1.3.2 Potenti al benefi ts to patients ............................................................................... 23
1.3.3 Concl usion......................................................................................................... 23
1.4 Study  design ...................................................................................................... 23
2. STUDY OBJECTIVES ...................................................................................... 26
2.1 Primary object ive............................................................................................... 26
2.2 Secon dary object ives.......................................................................................... 26
2.3 Safety objectives................................................................................................ 27
2.4 Exploratory  objectives....................................................................................... 27
3. PATIENT SELECTION, E NROLMENT, RANDOMISAT ION, 
RESTRICTIONS, DISCONTINUATION AND WITHDR AWAL ..................... 29
3.1 Inclusio n criteria................................................................................................ 30
3.2 Exclusio n criteria............................................................................................... 30
3.3 Patient enrolment and rando misat ion.................................................................. 31
3.4 Procedures for handling incorrectly enro lled or randomised pat ients.................. 32
3.5 Methods for assigning treatment groups ............................................................. 32
3.5.1 Stratificat ion and capping ................................................................................... 33
3.5.1.1 Stratificat ion...................................................................................................... 33
3.5.1.2 Capping ............................................................................................................. 33
Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
11 (98)3.6 Methods for ensuring blinding ........................................................................... 33
3.7 Methods for unblinding ...................................................................................... 34
3.7.1 Unblinding for bioanalyt ical laboratory  personnel .............................................. 34
3.8 Restrictions ........................................................................................................ 34
3.9 Discontinuati on of  investigat ional product ......................................................... 34
3.9.1 Evaluat ion of vo lume status and invest igational prod uct (IP) dose 
reducti on/interrupti on......................................................................................... 35
3.9.2 Invest igational product (IP) restart or dose increase fro m dapagliflozin 5 mg 
to 10 m g or m atching placebo ............................................................................ 36
3.9.3 Procedures for discont inuat ion of a patient from investigational product (IP) .....36
3.9.3.1 Patient undergoes the premature treatment discont inuat ion visit (PTDV) and 
continues according to plan ................................................................................ 37
3.9.3.2 Patient agrees to undergo modified fo llow-
up.................................................... 37
3.10 Criteria for wi thdrawal ....................................................................................... 37
3.10.1 Screen failures ................................................................................................... 37
3.10.2 Withdrawal o f informed consent ........................................................................ 37
3.11 Discontinuati on of  the study ............................................................................... 38
4. STUDY PLAN AND TIMIN G OF PROCEDURES ........................................... 39
4.1 Enrolment period ............................................................................................... 43
4.1.1 Visit 1, enrolment (day -14 ±7) .......................................................................... 43
4.2 Treatment period ................................................................................................ 44
4.2.1 Visit2, randomisat ion (day 0)............................................................................ 44
4.2.2 Visit3 (day 14 ±3) ............................................................................................. 45
4.2.3 Visit 4(day 60 ±7) ............................................................................................. 45
4.2.4 Visit5 (day 120 ±7) ........................................................................................... 46
4.2.5 Visit6, (day 240 ±14) ........................................................................................ 46
4.2.6 Visit 7, 8, 9 etc., on -site visi ts; (day 360 ±14 and; every  4thmonth).................... 47
4.2.7 Prem ature treatm ent discontinuation visit (PTDV) ............................................. 47
4.2.8 Study  closure visit (SCV) ................................................................................... 48
4.2.9 Unscheduled visits ............................................................................................. 49
4.3 Follow-up peri od (Not applicable) ...................................................................... 49
5. STUDY ASSESSMENTS .................................................................................. 49
5.1 Efficacy assessments .......................................................................................... 49
5.1.1 Endpoint reporting overview .............................................................................. 49
5.1.2 Classificat ion of death ........................................................................................ 50
5.1.3 Potenti al renal endpoints .................................................................................... 50
5.1.3.1 Endpoints related t o eGFR decline ..................................................................... 50
5.1.3.2 Dialysis and renal transplantation ....................................................................... 51
5.1.3.3 Doubling of serum creat inine ............................................................................. 51
5.1.4 Hospitalisat ion for heart failure .......................................................................... 51
Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
12 (98)5.1.5 New diagnosis of ty pe 2 diabetes (T2D) ............................................................. 51
5.1.6 Cardi ac ischaemic events ................................................................................... 51
5.1.7 Cerebrov ascular events ...................................................................................... 51
5.1.8 Patient reported outcomes (PROs) ...................................................................... 52
5.1.8.1 The Kidney Disease Qualit y of Life -36 (KDQOL™ -36).................................... 52
5.1.8.2 EuroQol  five-dimensio nal five-level  ques tionnai re (EQ -5D- 5L)......................... 52
5.1.8.3 Administrati on of  patient reported outcomes (PROs) .......................................... 52
5.2 Safety assessments ............................................................................................. 53
5.2.1 Laboratory  assessments ...................................................................................... 53
5.2.1.1 Unscheduled laboratory  assessments .................................................................. 54
5.2.2 Physical examinat ion......................................................................................... 54
5.2.3 Electrocardiogram (ECG) ................................................................................... 54
5.2.4 Vital signs .......................................................................................................... 55
5.2.4.1 Pulse and bl ood pressure (BP) ............................................................................ 55
5.2.4.2 Body  weight and heigh t...................................................................................... 55
5.3 Other assessments (not applicable) ..................................................................... 55
5.4 Pharmacokinet ics (PK) ....................................................................................... 55
5.4.1 Collect ion of samples ......................................................................................... 55
5.4.2 Determinat ion of drug concentration .................................................................. 55
5.4.3 Storage and destruction of pharmacokinet ics (PK) samples ................................ 55
5.5 Pharmacodynamics (not a pplicable) ................................................................... 56
5.6 Genet ics............................................................................................................. 56
5.7 Biomarker analysis ............................................................................................. 56
5.7.1 Storage, re -use and destruction of bio logical  samples ......................................... 56
5.7.2 Labelling and s hipment of bio logical  samples .................................................... 56
5.7.3 Chain o f custody  of biological sampl es.............................................................. 57
5.7.4 Withdrawal o f informed consent for donated bio logical samples ........................ 57
6. SAFETY REPORTI NG AND MEDICAL MANAG EMENT ............................. 58
6.1 Definit ion of adverse events ............................................................................... 58
6.2 Definit ions of serious adverse event (SAE) ........................................................ 58
6.3 Recording of adverse events ............................................................................... 58
6.3.1 Time period for collect ion of adverse events ...................................................... 58
6.3.2 Adverse even ts of interest .................................................................................. 59
6.3.2.1 Volume deplet ion............................................................................................... 59
6.3.2.2 Renal events ....................................................................................................... 59
6.3.2.3 Major hypoglycaemic events .............................................................................. 60
6.3.2.4 Fractures ............................................................................................................ 60
6.3.2.5 Diabetic ketoacidosis (DKA) .............................................................................. 60
6.3.2.6 Adverse events (AEs) leading to amputation and AEs leading to a risk for 
lower limb amputati ons (“preceding events”) ..................................................... 60
6.3.3 Follow-up of unreso lved adverse events ............................................................. 60
Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
13 (98)6.3.4 Variables ............................................................................................................ 60
6.3.5 Causalit y collection ............................................................................................ 61
6.3.6 Adverse events based on signs and symptoms .................................................... 62
6.3.7 Adverse events b ased on examinat ions and tests ................................................ 62
6.4 Reporting of serious adverse events (SAEs) ....................................................... 62
6.4.1 Reporting of serious adverse events (SAEs) considered to be potential 
endpo ints........................................................................................................... 63
6.5 Over dose ............................................................................................................ 63
6.6 Pregnancy .......................................................................................................... 64
6.6.1 Maternal exposure .............................................................................................. 64
6.7 Management of IP related toxicit ies (not applicable) .......................................... 64
6.8 Study  governance and oversight ......................................................................... 64
6.8.1 Execut ive Co mmit tee......................................................................................... 64
6.8.2 National Lea d Invest igator (NLI) Committee ..................................................... 65
6.8.3 Data Monitoring Committee (DMC) .................................................................. 65
6.8.4 Clinical Event Adjudicat ion (CEA) Committee .................................................. 65
6.8.5 Diabetic Ketoacidosis Adjudicat ion Committee T2D ......................................... 65
6.9 Medicat ion Error ................................................................................................ 66
7. INVESTIGATIONAL PROD UCT (IP) AND OTHER T REA TMENTS ............ 67
7.1 Ident ity of investigational product (IP) ............................................................... 67
7.2 Dose and treatment regimens ............................................................................. 67
7.3 Labelling ............................................................................................................ 68
7.4 Storage ............................................................................................................... 68
7.5 Com pliance ........................................................................................................ 68
7.6 Accountabilit y.................................................................................................... 68
7.7 Concomitant and other treatments ...................................................................... 68
7.7.1 Restricted medication ......................................................................................... 69
7.7.2 Prohibited medicat ion........................................................................................ 69
7.7.3 Recording of conco mitant treatm ent................................
................................... 69
7.7.4 Chronic kidney  disease (CKD) m edicati ons ....................................................... 69
7.7.5 Anti-diabetes treatm ent of pati ents wi th established diagnosi s of t ype 2 
diabetes (T2D )................................................................................................... 70
7.7.5.1 Use of medicat ions known to cause hy poglycaemia in ty pe 2 diabetes (T2D) 
patients .............................................................................................................. 70
7.7.6 Other concomitant treatment .............................................................................. 70
7.8 Post Study  Access to Study  Treatm ent............................................................... 70
8. STATISTICAL ANALYSES BY ASTRAZENECA (AZ) ................................. 70
8.1 Statistical considerat ions.................................................................................... 70
Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
14 (98)8.2 Sample size est imate .......................................................................................... 71
8.3 Definit ions of analysis sets ................................................................................. 71
8.3.1 Full analysis set (FAS) ....................................................................................... 71
8.3.2 Safety analysis set .............................................................................................. 71
8.4 Outcom e measures for analyses .......................................................................... 71
8.4.1 Primary outcome mea sure.................................................................................. 71
8.4.2 Secondary  outcom e measure .............................................................................. 71
8.4.3 Safety outcom e measure ..................................................................................... 71
8.4.4 Exploratory  outcom e measure ............................................................................ 71
8.5 Methods for statist ical analyses .......................................................................... 72
8.5.1 Hypotheses ........................................................................................................ 72
8.5.2 Closed testing procedure .................................................................................... 72
8.5.3 Analysis of the primary  variable (s) .................................................................... 72
8.5.4 Analysis of the secondary variables .................................................................... 73
8.5.5 Subgroup analysis .............................................................................................. 73
8.5.6 Interim analysis .................................................................................................. 73
8.5.7 Sensit ivity analysis ............................................................................................. 73
8.5.8 Analysis of safet y variables ................................................................................ 73
8.5.9 Exploratory  analysis ........................................................................................... 73
9. STUDY AND DATA MANAGEMENT BY ASTRAZENECA (AZ) ................ 73
9.1 Training of study  site personnel ......................................................................... 73
9.2 Moni toring of the study ...................................................................................... 74
9.2.1 Risk based qualit y management ......................................................................... 74
9.2.2 Source data ........................................................................................................ 75
9.2.3 Study  agreem ents................................
............................................................... 75
9.2.4 Archiving of study  docum ents............................................................................ 75
9.3 Study  timetable and end of study ........................................................................ 75
9.4 Data m anagement by  AstraZeneca (AZ) ............................................................. 75
10. ETHICAL AND REGULATO RY REQUIREMENTS ....................................... 76
10.1 Ethical conduct of the study ............................................................................... 76
10.2 Subject data protection ....................................................................................... 76
10.3 Ethics and regulatory  review .............................................................................. 76
10.4 Inform ed consent ............................................................................................... 77
10.5 Changes to the protocol and informed consent form (ICF) .................................. 77
10.6 Audits an d inspect ions....................................................................................... 78
11. LIST OF REFERENCES ................................................................................... 79
Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
15 (98)LIST OF TABLES
Table 1 Study  plan............................................................................................. 39
Table 2 Laboratory  variables .............................................................................. 54
LIST OF FIGURES
Figure 1 Study  design ......................................................................................... 25
LIST OF APPENDICES
Appendix A Addit ional Safet y Informati on............................................................... 82
Appendix B Inter national Airline Transportation Associat ion (IATA) 6.2 
Guidance Docum ent.............................................................................. 84
Appendix C New York Heart Associat ion (NYHA) Funct ional Cl assificat ion........... 85
Appendix D Patient Reported Outcome (PRO) questi onnaires .................................. 86
Appendix E Genet ic Research .................................................................................. 96
Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
16 (98)LIST OF ABBREVIATION S AND DEFINITION OF TERMS
The fo llowing abbreviat ions and special terms are used in this study  Clinical Study  Protocol .  
Abbreviation or 
special termExplanation
ACE -I Angiotensin converting enzyme inhibitor
ALP Alkaline phosphatase
ALT Alanine transaminase
ANC A Anti-neutrophil cytopla smic antibody
ARB Angiotensin receptor blockers
AST Aspartate transaminase
AZ AstraZeneca, spons or
BP Blood pressure
BUN Blood urea nitrogen
CABG Coronary artery bypass grafting
CEA Clinical Event Adjudication
CKD Chronic kidney disease
CRO Clinic al research organization
CSA Clinical study agreement
CSR Clinical study report
CV Cardiovascula r
DAE Discontinuation of investigational product due to adverse event
DGR Danger ous Goods Regulations 
DKA Diabetic ketoacidosis
DMC Data Monitoring Comm ittee
DMP Data management plan
E-code Enrolment number
EASD European Association of the Study of Diabetes
ECG Electrocardiogram
eCRF Electronic case report form
eGFR Estimated glomerular filtration rate
EMA European Medicines Agency
Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
17 (98)Abbreviation or 
special termExplanation
EQ-5D-5L EuroQo l five -dimensional five -level questionnaire
ESRD End stage renal disease
FAS Full analysis set
GCP Good Clinical Practice
GMP Good Manufacturing Practice
Hb Haemoglobin
HbA1c Glycated haemoglobin
hCG Hum an chorionic gonadotropin
HR Hazard ratio
IATA International Airline Transportation Association
IB Investigator’s brochure
ICF Infor med conse nt form
ICH International Conference on Harmonisation
IRB/IEC Institutional review board/independent ethics committee
International 
Ccoordinating
investig atorIf a study is conducted in several countries the International Coordinating 
Investigator is th e Investigator coordinating the investigators and/or 
activities internationally.  
IP Investigational Product (dapagliflozin or matching placebo)
ITT Inten tion to treat
IxRS Interactive Voice/Web Response System
KDQOL™ -36 Kidney Disease Quality of Life -36
MedDRA Medical Dictionary for Regulatory Activities
MI Myocardial infarction
NYHA New York Heart Association
PCI Percutaneous coronary intervention
PI Principal Investigator
PK Pharmacokinetics
PRO Patient reported outcomes
PTH Parathyroid horm one
PTDV Prem ature treatment discontinuation visit
RAAS Renin -angiotensin -aldosterone system
SAE Serious adverse event
Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
18 (98)Abbreviation or 
special termExplanation
SAP Statistical analysis plan
SCV Study closure visit
SED Study end date
SGLT2 Sodium glucose co -transporter 2
SU Sulfonylurea
T1D Type 1 diabetes
T2D Type 2 diabetes
TIA Transient ischemic attack
UACR Urine albumin creatinine ratio
ULN Upper limit of normal
WBDC Web based data c apture
Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
19 (98)1. INTRODUCTION
1.1 Background and rationale for conducting this study
Chronic kidney  disease ( CKD) affects approximately 10% of the adult populat ion worl dwide 
(Eckart et al 2013 ).  The m ost comm on causes of CK D are diabetes, hy pertensi on and chronic 
glomerulonephri tis.  Treatm ent for CKD encom passes angiote nsin convert ing enzyme inhibitor 
(ACE -I) and angiotensin II receptor blockers (ARBs), lipid and blood pressure (BP) control as 
well as a tight glucose contro l in diabetic pat ients.  
Dapagliflozin (Forxiga™/Farxiga™) is a highly  selective and reversible in hibitor of  the sodi um 
glucose co -transporter 2 (SGLT2), the major transporter responsible for glucose reabsorption in 
the kidney .  Dapaglifl ozin’s mechanism of action results in a direct and insulin independent 
eliminat ion of glucose by  the ki dneys, which resul ts in reduced blood glucose levels in 
type 2 diabetes (T2D) pati ents.  In addi tion, dapagliflo zin has a mild diuretic and natriuret ic 
effect.  The persi stent l oss of glucose wi th associ ated cal ories in the urine, results in a 
consistent and maintained reduct ion of the total body  weight, predominant ly a result of a 
reducti on in fat m ass including both visceral and subcutaneous adipose tissue.  Moreover, 
dapagliflozin has also been shown to reduce BP and albuminuria, two essent ial prognosti c risk 
factors for progression of CKD.  
There i s a growing body  of evidence indicating that SGLT2 inhibit ion is nephroprotective.  
This effect is thought to be achieved p artly by mechanisms independent of blood glucose 
reducti ons ( Rajasekeran et al 2016 , Heerspink at al 2016b ), such as reduced intra -glomerular 
pressure through an enhanced tubuloglo merular feedback m echanism  (De Nicol a et al  2014 , 
Thomas 2014), reduced gl ucose and sodi um transport over the proximal tubule cells ( Komala et 
al 2013 , Pollock et al 1991), increased natriuresis (Heerspink et al 2013 ) and reduced systemic 
BP (Baker et al 2015 , Sjöström  et al  2015a ).  Interestingly, there is a theoretical rationale for an 
impro ved oxy gen availabilit y in the impaired kidney  during dapagliflo zin treatm ent.  Thi s 
could potentially be achieved via two mechanisms.  First ly, an improved oxygen delivery  due 
to a small but consistent ly observed haemo -concentrati on and secondly through a reduced renal 
oxygen consumpt ion due to a reduced energy  requirem ent from the potassi um sodi um pum p 
situated on the basal -lateral  membrane striving to retai n the sodi um gradient over the tubular 
cells ( Gilbert RE 2016 , Korner et al 1994).  Finally, there are emerging theories around 
metabo lic benefits connected to a mild ketos is induced by SGLT2 inhibit ion (Mudaliar et al 
2016).
Notably, the total amount of gl ucose excreted in the urine following dapagliflo zin 
administration, declines with decreasing kidney funct ion and clinically important reduction i n 
glycated haemoglo bin (HbA1c) has not been demo nstrated in T2D patients with est imated 
glomerular filtrat ion rate (eGFR) <45 ml/min ( Kohan et al 2014 ).  However, similar reductions 
of non-glycaemic variables such as BP, body  weight and albuminuria have been observed wit h 
Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
20 (98)dapagliflozin ( Kohan et al 2014 ) and other SGLT2 inhibitors ( Barnett et al 2014 , Yale et al 
2013) in patients with impaired renal funct ion as in patients with normal rena l funct ion.  
Furtherm ore, post -hoc analyses of data from the dapagliflo zin phase II and phase III 
programme have shown in T2D patients with moderate renal i mpairment on renin -angiotensin -
aldosterone system  (RAAS) blo ckade a reduction of around 40% in albu minuria and 
stabilization of eGFR decline for up to one y ear (Sjöström  et al  2015b ) and two y ears  ( Fioretto 
et al 2016 ).  The EMPA -REG outcom e trial, examining the cardi ovascular (CV) eff ect of 
empaglifl ozin in T2D pati ents has further indicated beneficial renal effects of SGLT2 
inhibit ion.  After an init ial drop in eGFR, kidney  functi on was stable over time while a 
progressive decrease in eGFR was seen in the placebo group.  The trial als o suggested 
substant ial risk reduct ions for new onset of macroalbuminuria, doubling of serum creatinine 
and init iation of dialysis treatment ( Wanner et al 2016 ).  
Nephroprotective effects not related to glucose ex cretion, rationale for use in non -T2D
As indicated above many  of the effects fro m SGLT2 inhibit ion thought to contribute to a 
nephroprotective effect seem to be largely unrelated to glucose control per se.  Accordingly, 
regression analyses on data from the dapagliflozin phase III program indicate that the 
albuminuria lowering effect is not dependent on the glucose lowering actions seen during 
SGLT2 inhibit ion (Heerspin k et al  2016 , Fioretto et al 2016 ).  Furtherm ore, pool ed data from 
the phase III program does not indicate a reduced effect on volume constrict ion (as m easured 
by changes in haematocrit), systolic BP, pulse pressure, albuminuria and body  weight in 
subjects wi th low glucose excret ion due to renal impairment as compared wit h subjects 
excret ing larger amounts of glucose in the urine ( Sjöström et al 2016
, EASD 2016).
Data on the effec t of SGLT2 inhibit ion in pat ients without di abetes is limited.  However, 
dapagliflozin has safely  been administered in healthy  volunteers over a broad dose r ange (up to 
500mg given as single dose) ( Kasichayanula et al 2014 ).  Dapagliflozin effect ively inhibited 
SGLT2 al so in healt hy volunteers without any  observed events of hypoglycaemia.  
Furtherm ore, a clinical tri al with canagliflo zin, showed clinically  relevant BP and wei ght 
reducti ons in obese non -diabet ic pat ients without an increased incidence of hypoglycaemia 
(Bays et al 2013).  
Overall, the available data strongly ind icate that non -diabet ic CKD patients would also benefit 
from SGLT2 inhibit ion induced changes in va riables important for nephroprotection.  As a 
consequence, this study  will include CKD pat ients with and wi thout T2D.
1.2 Rationale for study design, doses and c ontrol groups
1.2.1 Rationale for study design and study population
This is a rando mised , doubl e-blind, p arallel- group study .  
Rando misat ionand double blinding 
will minimize potential bias.  Parallel group design was chosen because a crossover study  
cannot asse ss major renal outcome events.  The study  will be multicentre in numerous 
geographi c regi ons to pro vide a wide applicabilit y of resul ts.  
Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
21 (98)The study  popul ation chosen for this study  is a broad popul ation of patients with impaired 
kidney funct ion.  Pati ents with CKD are at high risk of CV events, terminal renal failure and 
death ( Go et al 2004).  Albuminuria adds to this risk, hence, the target populat ion will  have 
CKD (eGFR ≥25and≤75mL/min/1.73m2) with albuminuri a (urine albumin creat inine ratio 
[UACR] ≥200 and≤5000 mg/g).  However, patients with known po lycyst ic kidney disease, 
glomerulonephri tis with flares (lupus or anti -neutrophil cytoplasmic antibodies [ANCA] 
associ ated vasculi tis) or ongoing act ive renal in flammat ion will be excluded.
There i s scientific rationale for beneficial effects of SGLT2 inhibit ion also in pat ients with 
CKD bu t without di abetes.  Pati ents wi th CKD have similar clinical picture with increased 
intra-glomerular pressure, hypertensio n, protei nuria and fluid/sodium overload regardless o f 
underlying disease.  SGLT2 inhibit ion can improve on all these abnormalit ies th rough 
metabo lic-independent mechanisms.  Moreover, the reduction on CV and renal events with 
empaglifl ozin cannot be explained by the gl ucose lowering effect al one ( Rajasekeran et al 
2016, Mudaliar et al 2016 , Gilbert RE 2016 ).
1.2.2 Rationale for primary outcome measure
The pr imary outcom e measure is based on the requirements as outlined in the European 
Medicines Agency (EMA)’s draft guideline, which sta tes that a composite endpo int of ≥50% 
sustained decline in eGFR, end stage renal disease (ESRD) and renal death (death due to ESRD 
when dialysis is not given) are acceptable outcome measures ( EMA 2016 ).  Thi s endpo int has 
also been used in a number of previous outcome studies.  
CV m ortalit y is added as a component of the composite endpo int since CV mortalit y in the 
popul ation being studi ed is high and the risk for CV death correlates with the risk of developing 
ESRD.  Thus, CV mortalit y is a co mpet itive ri sk com ponent and dapagliflozin is expected to 
have a beneficial effect on both CV death and renal outcome ( Wanner et al 2016 ).
1.2.3 Rationale for secondary outcome measure 
It is of importance to separately look at the effect on co mposite renal endpo ints and the 
composite heart failure endpoints (hospitalisat ion for heart failure and CV d eath).  Heart failure 
is particularly co mmo n in pat ients with CKD.  SGLT2 inhibit ion has prev iously shown to have 
beneficial effects on heart failure outcomes in pat ients with T2D and established CV disease 
(Zinman et al 2015 ).  All-cause mortalit y will  be assessed as a secondary  endpoint because it is 
important to evaluate the effect of dapagliflozin on non -CV, as well as CV, mortalit y and hence 
overall mortalit y.
1.2.4 Rationale for dose selection
The m arketed dose, 10 mg, of dapagliflozin has been demo nstrated to be well tolerated and 
effect ive for the treatme nt of T2D and post hoc analyses in pat ients with CKD and albuminuria 
have shown that this dose effect ively reduces renal surrogate markers, i.e., BP and albuminuri a, 
independent of the glucose lowering effect.  In a dedicated CKD 3 study  (eGFR 30 to 60 
mL/min/1.73m2) this dose was found to be well tolerated ( Kohan et al 2014 ).  From  a 
pharmacokinet ics (PK) and pharmacodynami cs perspective, dapagliflozin 10 mg is appropriate 
Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 Mar ch 2020
22 (98)for use in patients with renal impairment.   The marketed 5 mg dose of dapagliflozin may be 
used in the study , but i t is expected to provide less inhibit ion of SGLT2 and thus exert less 
pharmacodynamics eff ects (for details on when 5 mg or m atching pl acebo can be used, see 
Secti on 3.9.1 ).
1.3 Benefit/risk and ethical assessment 
Dapagliflozin has global market approval and based on global cumulative sale figures up to
March 2016 it is est imated that dapagliflozin has been administered for >1 000 000 patient 
years.
1.3.1 Potential risks
The potential risks of treatment with dapagliflozin are described in the Invest igator’s Brochure 
(IB).  Addit ional considerations relevant fo r the target population are described below.  
Dapagliflozin has not been shown to induce hyp oglycaemia in non -diabetes pati ents.  In 
clinical pharmaco logy studi es, heal thy subjects have been treated with single oral doses up to 
500mg and mult iple oral do ses of 100 mg up to 14 days without any  hypoglycaemic event.
Events related to volume deplet ion (including reports of dehydration, hypovo lemia, or 
hypotension) and events related to changes in renal funct ion have been thoroughly evaluated in 
the dapagliflo zin phase III program.  In a large pool consist ing of 21 active -and placebo -
controlled stud ies, serious adverse events (SAEs) of vo lume deplet ion were infrequent ly 
reported and the proportion was even lower for subjects treated with dapagliflozin than co ntrol 
(0.1% versus 0.2%).  SAEs of renal impairment/failure were also rarely reported and bal anced 
between treatment groups in the clinical trial program.  In total, 9 (0.2%) SAEs were reported 
in the dapagliflozin group and 5 (0.1%) SAEs in the control gr oup.  
Although the phase III data in pat ients with CKD 3 show an increased frequency of over all 
renal events in patients treated with dapagliflozin as compared with placebo, most of these 
events have been related to laboratory  detected transient increases in creat inine.  
In an analysis using pooled data on a subset of patients with CKD 3, micro or macro 
albuminuria and treatment with ACE -I or ARB there was no meaningful difference between 
dapagliflozin and placebo in terms of SAEs of renal impairment/fail ure or SAEs of volume 
depletion (Sjöström  et al  2015b ).  
Similarly , in a recent analysis o f patients with pre- exist ing heart failure (HF) using pooled data 
from previ ous dapagliflozin studies ( Kosiborod et al 2016), the rate of hypovo lemic events was 
similar between patients trea ted wi th dapagliflozin and patients treated with placebo.  
Loop -diuret ics are widely used in the target patient population and are also allowed in this 
study .  Inthe dapagliflozin phase III program, patients using loop diuret ics were more likely to 
have an event rel ated to vol ume deplet ion regardless of whether they  were treated wi th 
dapagliflozin or placebo.  A pooled analysis o f the short -term treatm ent peri ods showed 
6(2.5%) subjects with events in pat ients on dapagliflo zin 10 mg and 4 (1.5%) in patie nts on 
Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
23 (98)placebo.  When including the long -term extensio n peri ods of  the phase III trials in the analysis, 
the corresponding values were 7 (3.0%) versus 7 (2.7%) fordapagliflozin and placebo, 
respectively .  
Furtherm ore, other post hoc safet y analyses of im portance to the current target populat ion have 
not identified any indicat ion of an increased risk of marked abnormalit ies in potassium levels 
(≥6mmo l/L) in either patients with CKD 3 and ACE -I/ARB treatment ( Sjöström  et al  2015b )
or in patients on concomitant treatment with potassium sparing agents ( Kosiborod et al 2016). 
1.3.1.1 Protection against risks
This study  has been designed with appropriate measures in place to monitor and minimize any  
potenti al heal th risks to parti cipat ing pat ients.  In order to ensure the safet y of all patients 
participat ing in AstraZeneca (AZ) sponsored studies, reviews of all safet y informat ion from all 
ongoing clinical dapagliflozin studies are conducted as they  become available.  In addit ion, an 
independent Data Monitoring Co mmittee (DMC) will be responsible for safeguarding the 
interests of the patients by reviewing safet y data throughout the study .
1.3.2 Potential benefits to patients
In thi s study , the dose of dapaglif lozin 10 mg was chosen based on previous clinical 
experience.  Dapagliflozin is believed to be nephroprotective through non -glycaemic 
mechanisms and the hypothesis is that patients treated with dapagliflozin will have delayed 
progression of CKD and reducti on in CV m ortali ty.  Dapagliflozin has been shown to reduce 
UACR, HbA1c, BP and body  weight in pati ents with T2D.  
Patients, i rrespect ive o f treatm ent, in clinica l studies m ay receive greater m edical care/attention 
than in ordinary  clinical  pract ice.
1.3.3 Conc lusion
At the time of writ ing this clinical study protocol, no available SGLT2 inhibitors are indicated 
for treatm ent of CKD in pat ients with and wi thout T2D.  Con sidering the non -clinical and 
clinical experience with dapagliflozin and the precautions incl uded in the study protocol , 
participat ion in this study shoul d present a minimal and thus acceptable risk to patients who 
meet the inclusio n/exclusio n criteria and consent to take part in the study.
1.4 Study design 
This is an international, mult icentre, even t-driven, rando mised, double -blind, parallel -group, 
placebo -controlled study , evaluat ing the effect of dapagliflozin 10 mg versus placebo, given 
once daily  in addi tion to standard of care, to prevent the progression of CKD or CV/renal death.  
It is estima ted that approximately 10 000 pati ents at approximately 450 study  sites in 
approximately  20countries will be enrolled to reach the target of approximately 
4000 randomised patients.
Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
24 (98)The ant icipated durati on of  the study  is approximately 45 months.  The stu dy closure 
procedures will be init iated when the predetermined number of primary endpo ints is predicted 
to have occurred (n=681), i.e., the study  end date (SED) (s ee Figure 1).  The study  durati on 
may be changed if the event rate or randomisat ion rate is different than anticipated.  The study  
may be terminated early if eit her a clear beneficial or harmful effect of the study  treatment i s 
detected during the DMC review.
Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
25 (98)Figure 1 Study design

Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
26 (98)2. STUDY OBJE CTIVES
2.1 Primary objective
Primary Objective: Outcome Measure:
To determine if dapagliflozin is superior to 
placebo in reducing the incidence of the primary 
composi te endpoint of ≥50% sustained decline in 
eGFR, reaching ESRD, CV or renal death when 
added to current background therapy in patients 
with eGFR ≥25 and ≤75 mL/min/1.73m2and 
albuminuria (UACR ≥200 and ≤5000 mg/g).Time to the first occurrence of any of the 
components of this composite: 
1. ≥50% sustained* decline in eGFR 
2. Reaching ESRD 
Sustained* eGFR 
<15mL/min/1.73m2or, 
Chronic* dialysis treatment or,
Receiving a renal transplant
3. CV death 
4. Renal death
*As defined in the Clinical Event Adjudication (CEA) ch arter
2.2 Secondary objectives
Secondary Objective: Outcome Measure:
To determine whether dapagliflozin compared 
with placebo will result in a reduction of the 
incidence of the composite endpoints of 
worsening of renal function.  Time to the first occurrenc e of any of the 
components of this composite: 
1. ≥50% sustained decline in eGFR
2. Reaching ESRD
3. Renal death
To determine whether dapagliflozin compared 
with placebo will result in a reduction of the 
incidence of the composite endpoint of CV death 
or hospitalisation for heart failure.  Time to the first o ccurrence of either of the 
components of this composite: 
1. CV death 
2. Hospitalisation for heart failure 
To determine whether dapagliflozin compared 
with placebo will result in a reduction of the 
incidence of all -cause mortality.  Time to death from any ca use
Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
27 (98)2.3 Safety objectives 
Safety Objective: Outcome Measure:
To evaluate the safety and tolerability of 
dapagliflozin in this patient population.  1. S erious adverse event (SAE)
2. Discontinuation of investigational 
product (IP) due to adverse event 
(DAE)s
3. Changes in clinical 
chemistry /haematology parameters
4. AEs of interest (volume depletion, 
renal events, major hypoglycaemic 
events, fractures, diabetic ketoacidosis 
(DKA), AEs leading to amputation and 
AEs leading to a risk for lower limb 
amputations [“preceding events”])
2.4 Exploratory objectives  
Exploratory Objective: Outcome Measure:
To determine whether dapagliflozin compared 
with placebo will result in a reduction in the 
incidence of the composite endpoint of chronic 
dialysis, renal death or receiving a ren al 
transplant.Time to the first occurrence of any of the 
components of this composite:
1. Chronic dialysis
2. Receiving renal transplant 
3. Renal death
To determine whether dapagliflozin compared 
with placebo will result in a reduction of the 
incidence of the individual components of the 
primary endpoint.Time to the first occurrence of each of the 
individual components:
1. ≥50% sustained decline in eGFR
2. Reaching ESRD 
3. CV death
or
4. Renal death
Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
28 (98)Exploratory Objective: Outcome Measure:
To deter mine whether dapagliflozin compared 
with placebo will result in a reduction of the 
incidence of sustained reduction in kidney 
function.Time to the first occurrence of two conse cutives 
central laboratory values showing either of the 
following:
1. ≥30% decline in eGFR from baseline
2. ≥40% decline in eGFR from baseline
To determine whether dapagliflozin compared 
with placebo will have an effect on eGFR over 
time.  The effect on eGFR o ver time will be measured:
1. From baseline to end of treatment
2. From first on treatment measurement 
to end of treatment
To determine whether dapagliflozin compared 
with placebo will result in a reduction of the 
incidence of patients reaching CKD 4 (eGFR 
<30mL/min/1.73m2).Proportion of patients with eGFR >40 
mL/min/1.73m2at baseline that enter CKD 4 
during the study.
To determine whether dapagliflozin compared 
with placebo will have effect on UACR.Changes in UACR from baseline.
To determine whether dapag liflozin compared 
with placebo will result in a reduction of the 
incidence of hyper - and hypokalaemia.  Time to the first occurrence of each of any of the 
following central laboratory levels of serum 
potassium:
 >6.0 mmol/L
 >5.5 mmol/L
 <3.5 mmol/L
 <3.0 mmo l/L
To determine whether dapagliflozin compared 
with placebo will result in a reduction of the 
incidence of events of doubling of serum 
creatinine.Time to the first occurrence of an event of 
doubling of serum creatinine (compared to the 
most recent centr al laboratory measurement)
To determine whether dapagliflozin compared 
with placebo will result in a reduction of the 
incidence of new diagnosis of T2D in patients 
without diabetes at baseline.Proportion of patients without diabetes at baseline 
with a ne w diagnosis of T2D during the study
To determine whether dapagliflozin compared 
with placebo will have effect on HbA1c in T2D 
patient subgroup.Changes in HbA1c from baseline
Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
29 (98)Exploratory Objective: Outcome Measure:
To deter mine whether dapagliflozin compared 
with placebo will have an effect on systolic BP.Change in systolic BP from baseline
To deter mine whether dapagliflozin compared 
with placebo will have an effect on body weight.Change in body weight from baseline
To determine whether dapagliflozin compared 
with placebo will result in a r eduction in the 
incidence of the composite endpoint of CV death, 
MI or stroke.Time to the first occurrence of any of the 
components of this composite:
1.CV death
2.MI
3.Stroke
To deter mine whether dapagliflozin compared 
with placebo will result in a reduction in the 
incidence of heart failure hospitalisation .Time to first hospitalisation for heart failure
To deter mine whether dapagliflozin compared 
with placebo will result in a reduction in the 
incidence of myocardial infarction (MI).Time to first fatal or n on-fatal MI
To determine whether dapagliflozin compared 
with placebo will result in a reduction of the 
incidence of any stroke (ischemic, haemorrhagic, 
or undetermined).Time to first fatal or non -fatal stroke of any cause
To compare the effect of dapagl iflozin versus 
placebo on the Kidney Disease Quality of Life -36 
(KDQOL™ -36) questionnaire.Change from baseline in the overall summary 
score of the KDQOL™ -36 
To compare the effect of dapagliflozin versus 
placebo on health status assessed by EuroQol five -
dimensional five -level questionnaire (EQ -5D- 5L) 
to support health economic analysis and health 
technology assessment.Changes in health status measured by the 
EQ-5D-5L
To collect and analyse PK samples for 
dapagliflozin concentration.Not applicable. Resu lts will be reported 
separately.
To collect and store blood/urine samples for future 
exploratory biomarker and genetic research.Not applicable. Results will be reported 
separately.
3. PATIENT SELECTION, E NROLMENT, RANDOMISAT ION, 
RESTRICTIONS, DISCON TINUATI ON AND WITHDRAWAL 
Each patient should meet all o f the inclusio n criteria and none of the exclusio n criteria for this 
study .  Under no ci rcumstances can there be exceptions to this rule.  
Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
30 (98)3.1 Inclusion criteria
For inclusio n in the study  patients shoul d fulfil the fo llowing criteria:
1. Provisio n of signed informed consent prior to any study specific procedures
2. Female or m ale aged ≥18 y ears at the time of consent
3. eGFR ≥25 and ≤75 mL/min/1.73m2(CKD -EPI Formula) at vi sit 1
4. Evidence of increased albuminuria 3 month s or m ore before visit 1 and UACR 
≥200 and ≤5000 mg/g at visit 1
5. Stabl e, and for the patient maximum tolerated labelled daily dose, treatment with 
ACE -I or ARB for at l east 4 weeks before visit 1, if not m edically  contraindicated
3.2 Exclusion criteria
Patients should not enter the study  if any of the fo llowing exclusio n criteria are fulfilled:
1. Autosomal do minant or autosomal recessive po lycyst ic kidney disease, lupus 
nephrit is or ANCA -associ ated vasculit is
2. Receiving cy totoxi c therapy , immunosuppressive therapy or other immunotherapy  
for primary or secondary  renal  disease wi thin 6 months prior to enrolment
3. History  of organ transplantation
4. Receiving therapy  with an SGLT2 inhibitor wi thin 8 weeks pri or to enrolment or 
previous intolerance of an SGLT2 inhibitor
5. Type 1 diabetes m ellitus (T1D)
6. New York Heart Associat ion (NYHA) class IV Congestive Heart Failure at the time 
of enrolment (see Appendix C)
7. MI, unstable angina, stroke or transient ischemic attack (TIA) within 12 weeks pri or 
to enro lment
8. Coronary  revascularizat ion(percutaneous coronary  intervent ion [PCI] or coronary  
artery  bypass graft ing [CABG]) or valvular repair/replacement within 12 weeks 
prior to enrolment or is planned to undergo any  of these procedures after 
rando misat ion
9. Any condi tion outsi de the renal and CV disease area, such as but not limited to 
malignancy, with a life expectancy of less than 2 years based on invest igator´s 
clinical judgement
Clinical Study Protocol
Drug Substance Dapaglif lozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
31 (98)10. Active malignancy requiring treatment at the time of visit 1 (wi th the except ionof 
successfully treated basal cell or treated squamous cell carcino ma).  
11. Hepati c impai rment (aspartate transaminase [AST] or alanine transaminase [ALT] 
>3x the upper limit of normal [ULN]; or total bilirubin >2x ULN at time of 
enrolment).  An iso lated in crease in bilirubin in patients with known Gilbert’s 
syndro me is not a reason for exclusio n.
12. Known blood- borne diseases such as specified in Appendix B(category  A and B).
13. Women of child- bearing potenti al (i.e., those who are not chemically or surgically 
sterilised or who are not post -menopausal) who are not willing to use a medically 
accepted method of contraception that is considered reliable in the judgment of the 
investigator, from the time of signing the informed consent throughout the study  
and 4 weeks thereafter , OR wom en who have a posit ive pregnancy test at enrolment 
or randomisat ion OR wo men who are breast -feeding.
14. Involvement in the planning and/or conduct of the study (applies to both AZ 
personnel and/or site personnel).
15. Previous rando misation in the present study.
16. Parti cipation in another clinical study  with an IP during the last month prior to 
enrolment.
17. Inabilit y of the pati ent, in the opi nion of the invest igator, to understand and/or 
comply with IP, procedures and/or follow-up OR any  condi tions that, in the opinio n 
of the invest igator, may render the patient unable to complete the study.  
 Patients who cannot complete the patient reported outcome (PRO) 
assessments can st ill participate in the study (see Section 5.1.8.3 for 
details regarding the patient exclusio n from the PRO assessments during 
certain circumstances).  
Procedures for withdrawal of incorrectly  enrolled pati ents see Secti on 3.4.
3.3 Patient enrolment and randomisation
Invest igator(s) should keep a record, the patient screening log, of patients who entered pre -
study  screening.  
The Investigator(s) will:
1. Obtain signed informed consent fro m the pati ent or thei r guardi an/leg al 
representative before any study  specific procedures are performed.
Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
32 (98)2. Assign the patient a unique enrolment number (E- code), beginning with ‘E#’, which 
will be used to identify the patient throughout the study .  The E -code to be assigned 
in the Interactive Voice/Web Response System (IxRS). 
3. Determine patient eligibilit y.  See Secti on 3.
4. At visit 2, perform the rando misat ion transact ion in the IxRS.
Re-enrolment is allowed one single time considering that the patient was not rand omised.  The 
same E -code that the patient received at the first enrolment will be used.  All enrolment 
assessments and procedures (see Section 4.1.1 ), including re -signing the inform ed consent 
form (ICF), shoul dbe performed again.  
3.4 Procedures for handling incorrectly enrolled or randomised 
patients
Patients who fail to meet the eligibilit y criteria shoul d not, under any  circumstances, be 
enrolled or receive IP.  There can be no except ions to this rule.  Patient s who are enrolled, but 
subsequent ly found not to meet all the eligibilit y criteria m ust not be rando mised or ini tiated 
on treatment, and must be withdrawn fro m the study. 
Where a patient does not meet all the eligibilit y criteri a but i s rando mised in err or, or 
incorrectly  started on treatm ent, the Invest igator should inform the AZ study physician 
immediately , and a discussi on shoul d occur between the AZ study  physician and the 
investigator regarding whether to continue or discont inue the patient fro m treatment. Study  
treatm ent m ust be di scont inued in all cases where continued treatment is deemed to pose a 
safet y risk to the patient. In those cases where continuat ion of study  therapy  is judged not to 
present a concern related to safety  and disease managem ent, the rati onale for continuing study  
therapy  must be cl early  documented. Regardl ess of what is decided about IP all randomised 
patients shoul d remain in the study  and the pati ents shoul d cont inue to be fo llowed up in 
accordance with defined study  procedur es. 
3.5 Methods for assigning treatment groups
Randomisat ion to IP will be performed via IxRS at visit 2 in balanced blocks to ensure 
approximate balance between the treatment groups (1:1).
The IxRS will allocate the IP through a randomisatio n scheme and prov ide the rando misat ion 
number and the appropriate Kit IDs fro m IP available at the study  site.  The randomisat ion
codes will be computer generated and loaded into the IxRS database.  
At all visits where IP is dispensed, site personnel will do a kit verific ation in IxRS before
provi ding the IP bottle to the patient.  
Detailed instruction on use of the IxRS system will be provided to study  sites.  
Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
33 (98)3.5.1 Stratification and capping
The recrui tment will be continuously mo nitored in order to achieve adequate proporti ons of 
patient sub -popul ations.
Randomisat ion of patients based on geographic region will be monitored to ensure a global 
representation.  Also, the proportion of patients not on ACE -I or ARB at randomisat ion, due 
to intol erance, will be monitored to ensur e that the target populat ion is reflected in regards to 
background therapy .
3.5.1.1 Stratification
Randomisat ion will be stratified in IxRS based on patients with and without T2D at the time 
of rando misat ion in order to ensure approximate balance between treatment groups within 
each sub -popul ation.  T2D at the time of rando misation is based on:
 Established diagnosis of T2D 
OR 
 HbA1c more or equal to 6.5% (48 mmo l/mol) shown at central laboratory  
test at enrolment (visit 1) 
Randomisat ion will also be stratified in IxRS for pati ents wi th UACR >1000 mg/g to ensure 
an equal proportion of patients in each treatment group.
3.5.1.2 Capping
The number of rando mised patients with and without T2D will be monitored in order to 
ensure a minimum of 30% in each sub- popul ation.  Rando misation may be capped in IxRS 
(i.e., no m ore patients in a specific sub -populati on can be randomised) if the pre -determined 
limit i s reached.
The number of pat ients with eGFR 60 to75mL/min/1.73m2at the time o f rando misat ion, 
shown wi th a laboratory  test at enrolment (visit 1), will be monitored and rando misat ion in 
IxRS m ay be capped to ensure that the number of patients in this sub -popul ation does not 
exceed approximately 10%.  
3.6 Methods for ensuring blinding
The blinding of treatment is ensured by  using a double -blind technique.  The dapagliflozin 
tablets and the respect ive placebo tablets will be ident ical in size, col our, sm ell, and taste.  The 
bottles wi th IP will be l abelled wi th unique ident ification numbers.  
No m ember of the extended AZ study  team , site personnel, or any  clinical research 
organi zation (CRO) handling study  data will have access to the randomisat ion scheme during 
the study .  The AZ personnel or delegate generat ing the rando misat ion scheme and the Supply  
Chain Study  Management may  be able to access the randomisat ion scheme as appropriate.  
Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
34 (98)3.7 Methods for unblinding 
Individual treatment codes, indicat ing the rando mised treatment for each patient, will be 
available to the Invest igator(s) or pharmacists from the IxRS.  Instructions for cod e breaking/ 
unblinding will be described in the IxRS user manual that will be provided to each site.  
The treatment code should not be broken except in medical emergencies when the appropriate 
management of the patient requires knowledge of the treatment randomisat ion.  The 
Invest igator documents and reports the action to AZ, without revealing the treatment given to 
patient to the AZ personnel.  It is always the investigator who decides when to unblind but it is 
recommended that the invest igator first cont acts th e AZ study  physician for consultation 
regarding the need for unblinding.  If unblinding is deemed necessary , the invest igator will 
perform  the unblinding in IxRS and must document all act ions taken.  The number of 
individuals at the study  site who b ecome aware of treatment status should be kept to the 
absolute minimum (including keeping the patient blinded if possible).  Treatment with study 
medicat ion shoul d be continued if possible.  
AZ retains the right to break the code for SAEs that are unexpec ted and are suspected to be 
causally  related to an IP and that potentially  require expedi ted reporting to regulatory  
authori ties.  Treatm ent codes will not be broken for the planned analyses of data until all 
decisio ns on the evaluabilit y of the data from  each individual pat ient have been made and 
docum ented.  
3.7.1 Unblinding for bioanalytical laboratory personnel 
PK samples will be analysed at the bioanaly tical laboratory  only  for pati ents on active IP.  The 
bioanalyt ical laboratory  will therefore have access to the treatment codes but will not share the 
codes with the sponsor or others invo lved in the study  until the blinding is broken for the 
study  after cl osure.
3.8 Restrictions
There are no specific dietary  or activi ty restri ctions.  For restricted concomitant medicat ions 
see Section 7.7.  
3.9 Discontinuation of investigational product
If the patient temporarily or permanent ly discontinues from IP, it is important that the 
scheduled study  visit s, data collect ion and pro cedures continue according to the study  protocol  
until study  closure (see Secti on 3.9.3 ).  
Patients m ay be di scontinued from IP in the fo llowing si tuations:
1. Patient deci sion.  The pati ent is at any  time free to discontinue treatm ent, wi thout 
prejudice to further treatment.
Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
35 (98)2. AE or other safet y reasons that, in the opinion o f the invest igator contraindicates 
further dosing with IP.
3. Severe non -compliance wi th the study  protocol .
4. DKA, consider to tem porary  interrupt IP if DKA is suspected.  If DKA is 
confirmed, IP should be discont inued permanent ly.  
5. Positive pregnancy  test (di scont inue IP and notify AZ representative).
3.9.1 Evaluation of volume status and investigational product (IP) dose 
reduction/interruption
Dapaglifl ozin is a SGLT2 inhibitor which by  its mechanism  of action reduces the reabsorption 
of glucose and sodi um in the proximal tubules in the kidney .  SGLT2 inhibit ion has a mild 
diuretic effect and an init ial haemodynamic change with an init ial increase in cre atinine may 
occur.
Unexpected acute declines in eGFR 
If an unexpected, acute decline in kidney function is observed, the patient should be evaluated.  
Volume deplet ion, hypotensio n, inter- current medical problems and concomitant drugs may 
cause increases in blood creatinine.  Urinary tract infect ion and urinary  obstructi on shoul d be 
considered (the latter especially in men).  Several drugs may  cause a decline in kidney  
funct ion, especially non -steroi dal anti-inflammatory drugs (NSAID) and certain ant ibioti cs 
such as trimethoprim.  If any  drug is suspected of causing or contribut ing to worsening kidney 
funct ion, their use should be re -considered.  
Volume depletion/hypotension
Patients wi th clinically relevant symptoms/signs o f suspected volume deplet ion and /or 
hypotension, should have their regular medication reviewed, and consideration given to 
reducing the dose of, or stopping conco mitant non -essent ial medicat ions, as assessed on an 
individual basis, including diuret ics and drugs that lower BP (except esse ntial treatm ents –see 
below).  The need for conventional diuretics (or the dose of diuretic used) should be re -
evaluated in light of the patient’s symptoms and signs.  In patients with heart failure, 
discontinuat ion of diuretic should only  be undertaken c autiously.  Hy potensi on may  also occur 
with other BP l owering drugs and once again the need for (and dose of) non -essent ia
l agents 
of this type (e.g., calcium channel blockers, alpha adrenoceptor antagonists and nitrates) 
shoul d also be re -considered.
Essential treatments
Essential disease modifying/evidence based treatments such as ACE -I/ARBs, for patients with 
proteinuric CKD and ACE -I/ARBs, sacubitril/valsartan, mineralocortico id receptor 
antagonists and beta -blockers for patients with heart failure, sho uld NOT be reduced in dose 
or discontinued unless all other measures fail to improve the patient’s situat ion. In the setting 
of acute worsening o f HF or other acute situations it may be acceptable to interrupt treatment 
Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
36 (98)on a temporary  basis in certain circ umstances (e.g., an ACE -I/ARB if the pat ient has 
experienced a significant deterioration in renal function, a beta -blocker if the pat ient is unduly  
bradycardic or hy potensive, a mineralocorticoid receptor antagonist (MRA) if the pat ient has 
hyperkalaemia).
IP dose reduction 
If the above ment ioned measures do not lead to a reso lution of clinically  relevant vol ume 
depletion, hypotension and/or unexpected worsening of kidney  function, a dose reduction of 
IP to dapagliflozin 5 mg or matching placebo may be con sidered and the patient’s condit ion 
re-evaluated.
Patients at risk of volume depletion
Temporary  interrupti on of  IP m ay be considered in patients thought to be at risk o f volume 
depletion/hypotension, such as pat ients with an acute m edical illness potentia lly causing 
volume depletion because of inadequate fluid intake or fluid/blood loss (e.g., gastroenteritis, 
gastrointestinal haemorrhage), or those undergoing major surgery .  
3.9.2 Investigational product (IP) restart or dose increase from dapagliflozin 5 mg to
10 mg or matching placebo
Restart of rando mised IP is always encouraged.  Even if a premature treatment discont inuat ion 
visit (PTDV) was completed due to the discont inuation of IP, this should not prevent the 
patient to return to randomised treatment if d eemed appropri ate.  
Every  attem pt shoul d be made to m aintain patients on dapagliflozin 10 mg or matching 
placebo during the course of the study .  If the dose has been decreased to 5 mg or interrupted, 
the dose should be increased back to dapagliflo zin 10 mg or matching placebo or 
re-introduced as soon as, in the opinio n of the investigator, the patient’s condit ion is stable.  
3.9.3 Procedures for discontinuation of a patient from investigational product (IP)
At any time, pati ents are free to discontinue IP.  A patient that deci des to di scont inue will 
always be asked about the reason(s) and the presence of any AEs.  If possible, the patient will 
be seen and assessed by  an invest igator.  Adverse events will be fo llowed up, see Section 6, 
and all IP should be returned by  the pat ient.
Generally, AEs, SAEs and potential endpo int events should not lead to IP discontinuation, 
unless there is a clear clinical rationale to do so.
Discontinuati on from IP is not the sam e as co mplete wi thdrawal  from the study .  If a pati ent is 
completely wi thdrawn from  study , see Secti on3.10.2 .
It is essent ial to collect data for all pat ients throughout the study .  Optimally , a pati ent who 
discontinue f rom IP shoul d for that reason attend all study  visit s according to plan until study  
closure.  Al ternat ively, if the patient does not agree to this approach, modified fo llow-up 
should be arranged.  Pati ents who agree to some kind of modified fo llow up are s till 
Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
37 (98)participat ing in the study.  The modified visit s and procedures that are done will be recorded 
in the electronic Case Report Form (eCRF).
If a patient for some reason cannot be reached during the study , every  attem pt shoul d be made 
to retri eve as much informat ion regarding this patient as possible.  The site should 
continuously try  to reach the pati ent, the patient’s family  or pre -ident ified appropriate contact 
person(s) and, search for informat ion regarding the patient’s status in applicable sources t o 
protect the validit y of data.  The attempts should be registered in the medical records.
3.9.3.1 Patient undergoes the premature treatment discontinuation visit (PTDV) and 
continues according to plan
The preferred follow -up approach for all patients who prematur ely and permanent ly 
discontinue IP i s that the pati ent undergoes the PTDV and then cont inues study visits 
according to plan ( Table 1).  The PTDV should be done as soon as possible after last IP dose.
3.9.3.2 Patient agrees to undergo modified follow -up
If the patient does not agree to continue study  visits according to plan, but agrees to undergo 
modified fo llow up, a PTDV should be done ( Table 1).  The subsequent visits unt il the s tudy 
closure will  be done as m odified foll ow-up (e.g., l ess frequent visits, regular telephone 
contacts, a contact at study  closure, or other means) in order to ascertain whether any  
endpo ints or safety  events have occurred.
3.10 Criteria for withdrawal 
3.10.1 Screen failures 
Screen failures are enrolled pat ients who do not fulfil the eligibilit y criteria for the study , and 
therefore m ust not be randomised.  These patients should have the reason for study  withdrawal  
recorded as ‘Screen failure’ (i.e., patient does no t meet the required inclusio n/exclusio n 
criteria) in the eCRF.  This reason for study  withdrawal  is only  valid for screen failures (not 
rando mised pat ients).  
3.10.2 Withdrawal of informed consent
Patients are free to withdraw from the study  at any time (IP and assessments), without 
prejudice to further treatment.  Withdrawal o f consent should only occur if the pat ient does 
not agree to any  kind of further assessments or contact whatsoever.  If agreed by the patient, a 
PTDV should be performed.  Discont inuat ion of IP in itself is not considered withdrawal of 
consent.  
Withdrawal o f consent m ust be ascertained and documented in writ ing by the investigator who 
must inform the AZ representative and document the wit hdrawal o f consent in the eCRF and 
medical records. 
A pat ient who wi thdraws consent will always be asked about the reason(s) and the presence of 
any AE.  The investigator will fo llow up AEs reported outside of the clinical study .
Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
38 (98)If a patient withdraws fro m participat ion in the study , then his/her enrolme nt and 
rando misat ion codes cannot be reused.  Withdrawn patients will not be replaced.  Data 
generated to the time of complete withdrawal fro m the study will not be destroyed.
To ensure validit y of study  data, i t is very  important to collect as much data a s possible 
throughout the study  and especially  vital status (dead or alive) at study  closure (also for 
patients who have withdrawn their informed consent).  The invest igator will therefore attempt 
to collect informat ion on all pat ients’ vital status from publicly available sources at study  
closure, even if informed consent has been withdrawn completely , in com pliance wi th local 
privacy  laws/pract ices.  
3.11 Discontinuation of the study
The study  may be stopped if, in the judgment of AZ, patients are placed at undue risk because 
of clinically relevant findings. The judgment may  be based on recommendations from the 
DMC, see DMC Charter for details.  
In terminat ing the study, the Sponsor will ensure that adequate considerat ion is given to the 
protecti on of  the pat ients’ interests.  
Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
39 (98)4. STUDY PLAN AND TIMING OF PROCEDURES 
The schedule of study  visits and assessments is shown in Table 1and explained further in Sections 4.1and 4.2.  
Table 1 Study plan
Activity Enrolment Randomi -
sationSite visit s Premature 
treatment 
discontinua -
tion visitStudy 
closure visitReference 
in CSP
Visit number 1 2 3 4 5 6 7, 8, 9 etc. PTDV SCV
Day -14
(±7)0 14
(±3)60
(±7)120
(±7)240
(±14)360
(±14 and 
every 4th
month)≤6 weeks 
from SED
Sign Informed Consent 
Form (ICF)X
Inclusion/exclusion criteria X X 3.1/3.2
Enrolment in IxRS X 3.3
Randomisation in IxRS X 3.3
Demography X
Medical/surgical history X
Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
40 (98)Table 1 Study plan
Activity Enrolment Randomi -
sationSite visit s Premature 
treatment 
discontinua -
tion visitStudy 
closure visitReference 
in CSP
Visit number 1 2 3 4 5 6 7, 8, 9 etc. PTDV SCV
Day -14
(±7)0 14
(±3)60
(±7)120
(±7)240
(±14)360
(±14 and 
every 4th
month)≤6 weeks 
from SED
Vital signs
(BP, pulse and body weight)X X X X X X X X X 5.2.4
Height X 5.2.4
Local laboratory 
assessmentaXa5.2.1
Central laboratory 
assessmentbX X X X X X X X X 5.2.1
Spot UACR, central 
laboratory samplingX X X X X X X X X 5.2.1
Pregnancy testing X X 5.2.1
Sample for biomarker 
research, if a pplicablecX Xc5.7
Sample for genetic research, 
if applicablecX Appendix E
Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
41 (98)Table 1 Study plan
Activity Enrolment Randomi -
sationSite visit s Premature 
treatment 
discontinua -
tion visitStudy 
closure visitReference 
in CSP
Visit number 1 2 3 4 5 6 7, 8, 9 etc. PTDV SCV
Day -14
(±7)0 14
(±3)60
(±7)120
(±7)240
(±14)360
(±14 and 
every 4th
month)≤6 weeks 
from SED
PK sampling (pre -dose) Xd5.4
Potential endpoints, SAEs 
DAEs etc, AEs of interesteXeX X X X X X X X 6
KDQOL™ -36 questionnaire X XfX X 5.1.8.1
EQ-5D-5L questionnaire X X X X fX X 5.1.8.2
General physical 
examinationX X X 5.2.2
Targeted physical 
examinationX X X X X 5.2.2
Electrocardiogram (ECG) X 5.2.3
Concomitant medication X X X X X X X X 7.7
Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
42 (98)Table 1 Study plan
Activity Enrolment Randomi -
sationSite visit s Premature 
treatment 
discontinua -
tion visitStudy 
closure visitReference 
in CSP
Visit number 1 2 3 4 5 6 7, 8, 9 etc. PTDV SCV
Day -14
(±7)0 14
(±3)60
(±7)120
(±7)240
(±14)360
(±14 and 
every 4th
month)≤6 weeks 
from SED
Dispense (including kit 
verification in IxRS)/Collect 
IPX X X X X X 3.5
IP compliance reminder X X X X X X
aLocal laboratory assessment is optional and may be used to assess eligibility (according to local routine) of eGFR and/or alb uminuria. If used, the ICF needs to be signed 
before the optional assessment starts. 
bCentral laboratory assessments include alkaline phosphatase (ALP), ALT, AST, bilirubin, blood urea nitrogen (BUN), creatinine (including eGFR assessment), 
haematocrit, haemoglobin (Hb), HbA1c, phosphate, potassium, a nd sodium will be analysed as specified in Table 2.
cBlood and urine samples for future biomarker and/or genetic research is optional.  The biomarker and/or genetic sampling is s ubject to separate consent by the p atient.  
Biomarker samples will be collected at visit 2 and 7, and genetic samples will be collected at visit 2.
dPK samples will be collected at visit 7.
eSAEs will be collected from the time of informed consent throughout the study until and including the patient’s last visit.  Potential endpoints, DAEs, AEs leading to dose 
reduction and temporary interruptions and AEs of interest will be collected from randomisation throughout the study until and including the patient’s last visit.
fThe PRO questionna ires will be completed as specified until visit 7 and thereafter every 12 months, and at PTDV and study closure visit (SCV).
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
43 (98)4.1 Enrolment period
4.1.1 Visit 1, enrolment (day -14 ±7)
During enro lment period the fo llowing assessments and procedures will be completed:
 Patient si gns the ICF before any study  procedures.
Patients who agree to the optional sampling of blo od and urine for 
potenti al future bi omarker and/or genet ic research will provide their 
consent.  
 Patient will be enrolled and assi gned an E-code in IxR S.
 Optional local laboratory assessment 
Failure to meet the criteria for eGFR and/or albuminuria is expected to be 
the main reason for screen failure in this study .  Therefore, si tes will  be 
allowed to perform an optional assessment, which will include lo cal 
laboratory  assessments of eGFR and/or albuminuria.  Invest igators will 
only assess pati ents who are potentially  eligible for the study  based on 
their medical condit ions and exist ing therapies, and only those who are 
expected to m eet all other entry  criteria.  
Local  laboratory  assessments of eGFR and/or albuminuria will be done 
according to local routine.
When the local result s of eGFR are available and indicate that the patient 
may be eligible based on the clinical judgement of the invest igator, the 
patient may  proceed to further enrolment procedures.
 The invest igator reviews the inclusion and exclusion criteria .  Pati ents 
who do not meet these criteria must not be rando mised in the study.  
 Demography (date of birth, sex, race, ethnic group) and relev ant medical 
and surgical history, including smoking history , will  be recorded.  
 Vital signs (BP, pul se and body  weight) and height will be assessed and 
recorded.
 Laboratory samples will be co llected and sent to the central laboratory  as 
specified in Table 2.  
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
44 (98)Due to high day  to day  variabilit y of creatinine (eGFR) and UACR, one 
central  laboratory  retest is allowed, if in the opinio n of the invest igator 
values are close to the inclusio n criteria.
 Pregnancy test forwom en of child- bearing potential will be done locally 
with a dipstick provided by central laboratory.
4.2 Treatment period
4.2.1 Visit 2, randomisation (day 0)
Prior to vi sit2, the investigator assesses eligibilit y based on the laboratory  resul ts received from  
central laboratory  from visit 1.  Pati ents not eligible will be considered screen failures and 
shoul d not continue to visit 2.  
At randomisat ion, the fo llowing assessments and procedures will be done:
 KDQOL ™-36 and EQ-
5D-5L will be completed by the patient p rior to 
any other site activit ies and before the patient meets the invest igator.
 The invest igator will re -assess the inclusion and exclusion criteria.
 The invest igator will perform a general physical examination.  
 Vital signs will be assessed and recorded
. 
 Electrocardiogram ( ECG ) will be done.
 Randomisation to IP will be done in IxRS.
For stratificat ion/capping purposes (see Section 3.5.1 ), informat ion 
about eGFR and UACR (based on results received fro m central
laboratory ), and whether pati ent has T2D or not will be recorded in 
IxRS.  
 Concomitant medication will be recorded.
 Laboratory samples will be co llected and sent to the central laboratory  as 
specified in Table 2.  
Patients who have consented to sampling for potential future 
biomarker analysis and/or genetic research , will  provide bl ood and 
urine samples.  
 Pregnancy test for wom en of child- bearing potential will be done locally 
with a dipstick provided by central laboratory .
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
45 (98) If the patient has experienced any SAEs since l ast visit, thi s will  be 
recorded in the eCRF.
 The IP will be dispensed via IxRS to the patient.  The patient will be 
instructed to take the IP in accordance wit h protocol without interruptions.  
4.2.2 Visit 3 (day 14 ±3)
At visit 3, the fo llowing assessments and procedure will be done:
 The invest igator will perform a targeted physical examination.  
 Vital signs will be assessed and recorded.
 Any relevant changes in concomitant medication will be recorde d.
 Laboratory samples will be co llected and sent to the central laboratory  as 
specified in Table 2.  
 If the patient has experienced any potential endpoints, SAEs, DAEs, 
and/or AEs of interest since the l ast vi sit,this will  be recorded in the 
eCRF.
 The patient will be reminded to take the IP in accordance wit h the protocol 
and wit hout interruptions.
4.2.3 Visit 4 (day 60 ±7)
At visit 4, the fo llowing assessments and procedure will be done:
 The invest igator will perform a targeted physical examination.  
 Vital signs will be assessed and recorded.
 Any relevant changes in concomitant medication will be recorded.  
 Laboratory samples will be co llected and sent to the central laboratory  as 
specified in Table 2.
 If the patient has experienced any potential endpoints, SAEs, DAEs, 
and/or AEs of interest since the l ast vi sit, this will  be recorded in the 
eCRF.
 The patient will be reminded to take the IP in accordance wit h the protocol 
and wit hout interrupt ions.  
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
46 (98)4.2.4 Visit 5 (day 120 ±7)
At visit 5, the fo llowing assessments and procedures will be done:
 EQ-5D-5L will be completed by the patient prior to any other site 
activit ies and before the patient meets the invest igator.  
 The invest igator will perform a targeted physical examination.  
 Vital signs will be assessed and recorded
.
 Any relevant changes in concomitant medication will be recorded.
 Laboratory samples will be co llected and sent to the central laboratory  as 
specified in Table 2.  
 If the patient has experienced any potential endpoints, SAEs, DAEs, 
and/or AEs of interest since the l ast vi sit, this will  be recorded in the 
eCRF.
 IP will be dispensed via IxRS to the patient and drug accountabilit y of the 
returned medication will be checked.  The patient will be instructed to take 
the IP i n accordance with the protocol and without interruptions.  
4.2.5 Visit 6, (day 240 ±14)
At visit 6, the fo llowing assessments and procedures will be done:
 EQ-5D-
5Lwill be completed by the pati ent pri or to any  other si te 
activit ies and before the patient meets the invest igator.  
 The invest igator will perform a targeted physical examination.  
 Vital signs will be assessed and recorded.
 Any relevant changes in concomitant medication willbe recorded.
 Laboratory samples will be co llected and sent to the central laboratory  as 
specified in Table 2.  
 If the patient has experienced any potential endpoints, SAEs, DAEs, 
and/or AEs of interest since the last visit, this will  be recorded in the 
eCRF.
 IP will be dispensed via IxRS to the patient and drug accountabilit y of the 
returned medicat ion will be checked.  The patient will be instructed to take 
the IP i n accordance with the protocol and wit hout inter rupti ons.  
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
47 (98)At visit 6, patient will be reminded to not take IP unt il after the visit at 
visit 7 to enable pre -dose PK sampling.  
4.2.6 Visit 7, 8, 9 etc., on- site visits; (day 360 ±14 and; every 4thmonth)
At visit 7 and all subsequent visits unt il SCV, the fo llowing assessments and procedures will be 
done:
 KDQOL ™
-36and EQ-5D-5L will be completed by the patient prior to 
any other site activit ies and before the patient meets the invest igator.  
The PRO questionnaires will be done at visit 7 and thereafter every 12 
months.  
 The invest igator will perform a targeted physical examination.  
 Vital signs will be assessed and recorded.
 Any relevant changes in concomitant medication will be recorded.
 Laboratory samples will be co
llected and sent to the central laborato ry as 
specified in Table 2.  
At visit 7, pre -dose, a PK sample will be collected.  The patient should 
not take IP before the visit this day .  The date and time of last dose 
before sampling will be recorded in eCRF .  
At visit 7, pati ents who have consented to sampling for potential future 
biomarker analysis , will provide blood and urine samples.  
 If the patient has experienced any potential endpoints, SAEs, DAEs, 
and/or AEs of interest since the l ast vi sit, this will be recorded in eCRF.
 IP will be dispensed via IxRS to the patient and drug accountabilit y of the 
returned medicat ion will be checked.  The patient will be instructed to take 
the IP i n accordance with protocol without interruptions.  
4.2.7 Premature treatmen t discontinuation visit (PTDV) 
Patients who prem aturely  and perm anent ly discontinue treatment with IP should return for a 
PTDV, whi ch will be done as soon as possible after last IP dose.  
 KDQOL ™-36 and EQ-
5D-5L will be completed by the patient prior to 
any other site activit ies and before the patient meets the invest igator.  
 The invest igator will perform a general physical examination.  
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
48 (98) Vital signs will be assessed and recorded.  
 Any relevant changes in concomitant medication will be recorded.
 Laborato ry samples will be co llected and sent to the central laboratory  as 
specified in Table 2.
 If the patient has experienced any potential endpoints, SAEs, DAEs, 
and/or AEs of interest since the l ast vi sit, this will  berecorded in the 
eCRF.
 Drug accountability of the returned medicat ion will be checked.  
Patients who discont inue treatment prematurely should attend all fo llowing study  visit s 
according to plan, including the SCV.
For further details regarding discont inuations fro m IP, refer to Section 3.9.
4.2.8 Study closure visit (SCV)
All patients will be asked to return for an SCV visit when the predetermined number of primary 
endpo ints is predicted to have occurred, i.e., the SE D.  All rando mised patients (including any 
patients who have discont inued treatment with IP) should return for their SCV visit as soon as 
possible but no later than 6 weeks after the SED.
 KDQOL ™-36 and EQ-5D-5L will be completed by the patient prior to 
anyother site activit ies and before the patient meets the invest igator.
 The invest igator will perform a general physical examination.  
 Vital signs will be assessed and recorded
 Any relevant changes in concomitant medication will be recorded.
 Laboratory sam ples will be co llected and sent to the central laboratory  as 
specified in Table 2
.  
 If the patient has experienced any potential endpoints, SAEs, DAEs, 
and/or AEs of interest since the l ast vi sit, this will  be rec orded in the 
eCRF.
 The patient will return remaining IP and drug accountability will be 
checked.  
After stopping IP the investigator should ensure that the patient is treated according to standard 
clinical practice and ascertain there is a proper medical follow-up pl an in place.
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
49 (98)4.2.9 Unscheduled visits
An unscheduled visit may  occur in -between scheduled visits e.g., to fo llow up on potential 
endpo ints such as re -sampling for eGFR (see Section 5.1.3.1 ).
4.3 Follow -up period (Not applicab le)
5. STUDY ASSESSMENTS
The Rave web based data capture (WBDC) system will be used for data collect ion and query  
handling.  The invest igator will ensure that data are recorded in the eCRFs in Rave as specified 
in the study  protocol  and in accordance with the eCRF instructions provided.  
The invest igator ensures the accuracy, completeness, and timeliness of the data recorded and of 
the provision o f answers to data queries according to the clinical study  agreement (CSA).
The invest igator will sign the complete d eCRFs.  A copy  of the com pleted eCRF will be 
archived at the study  site.  
5.1 Efficacy assessments
5.1.1 Endpoint reporting overview
Potenti al endpoints will  be identified through laboratory  data (refer to Table 2for laboratory  
assessments and t imings); when quest ioning the patient about his/her overall healt h; or through 
inform ation received through standard medical practice.  Invest igators will be encouraged to 
have a low thresho ld to submit any potential/possible event that might represent an endpoint.  
The fo llowing potenti al endpoints will be recorded in the eCRF and submitted for central 
adjudicat ion:
 All deaths
 Renal endpo ints:
Dialysis
Kidney transplantations
Doubling of serum creat inine (compared to the most rece nt central 
laboratory  measurement)
 Hospitalisat ionfor heart failure 
 Cardi acischaemic events (MI and unstable angina)
 Cerebrovascular events (stroke and TIA)
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
50 (98) DKA (not considered an efficacy variable but will be adjudicated as a 
safet y variable)
In addit ion, eGFR declines ≥50% fro m baseline, eGFR values <15 mL/min/1.73m2and new 
diagnosis of T2D will be recorded in the eCRF but will not be adjudicated.  
For each potential endpoint, the investigator or delegate will record the endpo int specific 
inform ationthe eCRF.  If the event is subject to adjudicat ion, rel evant source documents will 
be assembled.  The source documents and relevant eCRF data will be sent for central 
adjudicat ion.  
Detailed instructions regarding endpo int reporti ng will be provided to t he study sites.  
Addit ional details about the evaluat ions of potential endpoints will be described in the Clinical 
Event Adjudicat ion (CEA) charter.  
5.1.2 Classification of death
The CEA co mmittee members will adjudicate and classify all deaths based on defin itions 
described in the CEA charter.  For the purpose of the efficacy analysis, deaths will be sub -
classified into CV and non -CV as well as renal primary cause (death due to ESRD when 
dialysis is not given).  The invest igator will record the classificatio n of death as CV or non -CV 
death in the eCRF.  
5.1.3 Potential renal endpoints
5.1.3.1 Endpoints related to eGFR decline
eGFR baseline is defined as the mean central laboratory value from visit 1 and visit 2. 
Laboratory  values related to eGFR decline will trigger an a ction by  site in the foll owing 
situations: 
 Local laboratory values indicate that eGFR value has declined ≥50% 
compared wi th baseline, or i s below 15 mL/min/1.73m2.
As soon as possible, patient should come to the study  site for 
confirmat ion by a central l aboratory  testing. 
OR
 Central laboratory values, collected during a study visit, indicat ing that 
eGFR value has declined ≥50% com pared wi th baseline, or is below 
15mL/min/1.73m2.  
The central laboratory  will notify site if eGFR is <15 mL/min/1.73m2 or if there is ≥50% 
decline in eGFR compared to baseline. A re -sampling should be done at an unscheduled visit 
after at l east 4 weeks, and preferably no later than 6 weeks after the first sampling.  When a 
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
51 (98)central  laboratory  value is <15 mL/min/1.73m2 or if th ere is ≥50% decline in eGFR compared 
to baseline it should be recorded as a potential endpoint in the eCRF. 
The central laboratory  will calculate eGFR using CKD -EPI equati on (Levey  at al  2009 ).
5.1.3.2 Dialysis and renal transplantation  
If a patient starts dialysis and or go through a renal transplantation this will be recorded in the 
eCRF and submitted for adjudication.  
5.1.3.3 Doubling of serum creatinine
Doubling of serum creat inine (compared to the most rec ent central laboratory  measurem ent) 
will be recorded in the eCRF and submitted for adjudicat ion.  
Recording of doubling of serum creat inine co mpared to the most recent central laboratory result 
can be triggered by a local laboratory  resul t OR a central  laboratory  resul t.
5.1.4 Hospitalisation for h eart failure 
All potential hospitalizat ions for heart failure should be recorded in the eCRF and submitted to 
adjudicat ion.  The CEA committee members will adjudicate the events as specified in the CEA 
Charter.
5.1.5 New di agnosis of type 2diabetes (T2D)
New onset of T2D, post randomisat ion, is defined according to the fo llowing cri teria:
 Reporting of new onset of T2D necessitat ing initiation of  anti-diabet ic 
medicat ion 
OR
 HbA1c >6.5% (48 mmo l/mol) measured by central lab at two consecut ive 
study  visits
New onset of T2D will be recorded as an AE and on a separate eCRF page.  
5.1.6 Cardiac ischaemic events 
Sites shoul d record potenti al acute coronary  syndrom es such as MIs and unstable angina in the 
eCRF and submit for adjudicati on.  The CEA committee members will adjudicate all potential 
cardi ac ischaemic events to decide if they  qualify  as MIs according to the criteria defined in the 
CEA charter.
5.1.7 Cerebrovascular events
Sites shoul d record potenti al strokes and TIAs in the eCRF a nd submit for adjudicat ion.  The 
CEA co mmit tee m embers will adjudicate all potential cerebrovascular events to decide if they  
qualify  as stroke according to the criteria defined in the CEA charter.
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
52 (98)5.1.8 Patient reported outcomes (PROs)
PROs is an umbrella term referring to all outcomes and symptoms that are direct ly reported by 
the pati ent.  PROs have become important endpoints for regulatory  and reimbursement 
authori ties when evaluat ing effect iveness of treatments in clinical trials.  The fo llowing PROs 
will be administered in the study : KDQOL™ -36 and EQ -5D- 5L (see Appendix D).  Pati ents 
will be asked to complete the EQ -5D- 5L and the KDQOL™ -36 at the vi sits as specified in 
Table 1.
5.1.8.1 The Kidney Di sease Quality of Life -36 (KDQOL™-36)
The KDQOL™ -36 is an abbreviated form of the KDQOL, which is a self
-reported 
questionnaire that combines generic and disease -specific co mponents for assessing the healt h-
related quali ty of life of pati ents wi th CKD, see Appendix D.  
5.1.8.2 EuroQol five -dimensional five -level questionnaire (EQ -5D- 5L)
The EQ -5D- 5L is a self -reported questionnaire that is used to derive a standardized measure of 
healt h status, al so referred to as a utilit y score, see Appendix D.  EQ -5D- 5L utilit y scores are 
widely accepted by  reimbursement authorit ies and will be used to support health econo mic 
evaluat ions.  
5.1.8.3 Administration of patient reported outcomes (PROs)
All PROs will be administered electron ically.  Randomised pat ients will co mplete the PRO 
assessments at site using the same handheld electronic device (ePRO).  Each site must allocate 
the responsibilit y for the administration of the ePROs to a specific individual and, if possible, 
assign a bac kup person to cover if that individual is absent.  
All assessments should be completed as follows:
 Patient m ust not receive help from relat ives, friends, or site personnel to 
answer or clarify  the PRO quest ionnaires, in order to avoid bias.  If a 
patient uses visual aids (e.g., spectacles or contact lenses) for reading and 
does not have them at hand, the patient will be exempted fro m completing 
the PROs questionnaires on that visit.
 Before any  other study  procedures are conducted at a given visit.
 Before b eing seen by the invest igator.
 PRO questionnaires must be completed by the patient in private.
 The appointed site personnel should explain to patient the value and 
relevance o f ePRO assessments and inform that these quest ions are being 
asked to find out, d irectly fro m patients, how he/she feels.  The appointed 
site personnel shoul d also stress that the information is confident ial.
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
53 (98) The appointed site personnel must show patients how to use the ePRO 
device, in accordance with the instructions provided.
 The ap pointed si te personnel shoul d remind pat ients that there are no right 
or wrong answers, and the patient should be given sufficient time to 
complete the PRO questi onnai res.
 If the patient is unable to read the questionnaire (e.g., is blind or illiterate), 
the patient will be exempted from co mpleting the PRO questionnaires and 
may st ill part icipate in the study .
5.2 Safety assessments
5.2.1 Laboratory assessments
Blood and urine samples for determinat ion of clinical chemistry , haematol ogy, and urinalysis 
will be taken at the times indicated in Table 1.  The date of central laboratory  sample collect ion 
will be recorded in the eCRF, excluding local laboratory samples if taken at enrolment.  All 
laboratory  samples will be analysed at the central  laboratory , with the except ion of urine human 
chori onic gonadotropin (hCG) (pregnancy test, using a dipstick provided by the central 
laboratory ), and laboratory  samples taken at enrolment, which will be analysed locally.
All samples should b e taken by adequately trained site personnel and handled in accordance 
with instructi ons in the Laboratory  Manual .  Up to date reference ranges will be provided 
during the study  and l aboratory  resul ts will  be compared wi th the laboratory  standard norm al 
ranges and reported back to site.
Samples sent to the central laboratory  will be collected, labelled, stored and shipped as detailed 
in the Laboratory  Manual.
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
54 (98)The fo llowing laboratory  variables will be measured:
Table 2 Laboratory va riables
Haematology Clinical chemistry 
Haemoglobin (Hb)bAlanine transaminase (ALT)b
HaematocritaAlkaline phosphatase (ALP)b
Aspartate transaminase (AST)b
Urinalysis (dipstick) Bilirubinb
hCG (pregnancy test) Blood urea nitrogen (BUN)a
Creatinine (including eGFR assessment)a
Spot urinalysis HbA1ca
U-Albumin (including UACR assessment)aPhosphatec
U-CreatinineaPotassiuma
Sodiuma
aCentral laboratory analysis at all visits
bCentral laboratory analysis at visit 1, PTDV and SC V
cCentral laboratory analysis at visit 2, 5, PTDV and SCV
The Investigator should make an assessment of the laboratory  resul ts wi th regards to clinically  
relevant abnorm alities.  The l aboratory  resul ts shoul d be si gned and dated and retained at the 
study site as source data for l aboratory  variables.  
5.2.1.1 Unscheduled laboratory assessments
Unscheduled laboratory  samples will be requested by  the central  laboratory  for follow-up on 
e.g., eGFR values.  Follow -up samples related to eGFR should be collected durin g an 
unscheduled visit and sent to central laboratory  for analysis.  
5.2.2 Physical examination
A general physical examinat ion, including vo lume status, will be performed at the time of 
rando misat ion and when the pat ient stops IP.  
A targeted physical examinat ion with focus on volum e status will be performed as specified in 
the study  plan (see Table 1).
The assessment dates will be recorded in the eCRF.
5.2.3 Electrocardiogram (ECG)
A 12 -lead ECG (standard ECG with a paper sp eed of 25 to 50 mm/second covering at least 
6sequent ial beats) will be recorded at randomisation (visit 2) after the pati ent has been lying 
down to rest for at least 5 minutes.  The baseline ECG should be made available for CEA upon 
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
55 (98)request, to facilit ateadjudicat ion of potenti al cardiac i schaemic events.  The ECG date will be 
recorded in the eCRF.  
5.2.4 Vital signs
Vital signs will  be assessed according to the study  plan, Table 1.
5.2.4.1 Pulse and blood pressure (BP)
Pulse and BP will be measured three times at all visits, and all measurements will be recorded 
in the eCRF.  The measurements should be done before any  blood sam pling using a 
standardized cuff adapted to the size of the patient’s arm after the patient has been s itting and 
resting for least 5 minutes.  Preferably, the same arm should be used at all visit s.
5.2.4.2 Body weight and height
The patient’s body  weight will be measured with light clothing and no shoes at all visits.  If the 
patient has a prosthetic limb, this sh ould be consistent ly worn or not worn during all weight 
measurements.  The patient’s height will be measured at visit 1, wi th no shoes.  The weight and 
height will be recorded in the eCRF.  
5.3 Other assessments (not applicable) 
5.4 Pharmacokinetics (PK)
5.4.1 Collect ion of samples
One pre -dose bl ood sam ple for determinati on of  the dapagliflo zin concentration in plasma will 
be taken at visit 7.  Inform ation about l ast intake of IP and sampling ID, date and time will be 
recorded in the eCRF.  
Samples will  be collected, labelled stored and shipped as detailed in the Laboratory  Manual.
5.4.2 Determination of drug concentration
Samples for determination of dapagliflozin concentration in plasma will be analysed by  the 
bioanalyt ical laboratory  on behalf of AZ, using an appropriate validated bioanalyt ical method.  
Full details o f the analy tical method used will be described in a separate bioanaly tical report.  
5.4.3 Storage and destruction of pharmacokinetics (PK) samples
PK samples will be analysed during the course of the study  and dis posed of after the 
Bioanaly tical Report finalizat ion or six mo nths after issuance of the draft Bioanalyt ical Report 
(whichever is earlier).  The results of the PK analyses will be kept at the laboratory  until the 
end of the study  to prevent unblinding.  
PK samples may be disposed of or destroy ed and anonymised by  pooling.  Addi tional analyses 
may be conducted on the anonymised, pooled PK samples to further evaluate and validate the 
analyt ical method.  Any results fro m such analyses may  be reported separate ly from the clinical 
study  report (CSR).
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
56 (98)Incurred sample reproducibilit y analysis, if any , will  be perform ed al ongside the bioanalysis of 
the test samples.  The results from the evaluat ion will not be reported in the CSR but separately 
in a Bioanaly tical Report.  
5.5 Pharmacodynamics (not applicable)
5.6 Genetics
Refer to Appendix Efor details regarding optional genet ic sampling.  
For wi thdrawal  of consent to the opti onal genet ic sampling, refer to Section 5.7.4 .  
5.7 Biomarker analysis 
Serum  and plasma as well as urine will be co llected and stored for potential future analysis for 
exploratory  biomarkers to assess correlat ions wit h disease act ivity, effects of dapagliflozin, 
clinical outcomes an d toxi city.  Biomarker sam ples will  be collected, handled and shipped as 
detailed in the laboratory  manual .  
It is mandatory  to ob tain the pati ent’s consent to the donation and use o f biological samples.  
The consent date will be recorded in the eCRF.  Pa tient not consenting to donate bio logical 
samples for future bio marker analysis are still able to participate in the study , but wi thout 
provi ding sam ples f or biomarker analysis.  
The bio markers to be studied will be selected on possible relevance on patho physio logy of  the 
studi ed diseases.
5.7.1 Storage, re -use and destruction of biological samples
Samples will  be stored i n AZ bio bank for a maximum of 15 years fro m the date of the l ast 
patient’s last visit, after which they  will be destroyed.  The results of thi s biomarker research 
will be reported either in the CSR itself or as an addendum, or separately in a scient ific report 
or publicat ion.  The results of this biomarker research may be pooled with bio marker data from 
other studi es wi th dapaglifl ozin to genera te hypotheses to be tested in future research.  
5.7.2 Labelling and shipment of biological samples
The Principal Invest igator (PI) ensures that samples are labelled and shipped in accordance 
with the Laboratory  Manual and the Bio logical Substance, Category  B Re gulat ions (materials 
containing or suspected to contain infect ious substances that do not meet Category  A cri teria), 
see Appendix B.  
Any samples ident ified as Infect ious Category  A materi als are not shipped and no further 
sample s will be taken from the patient unless agreed with AZ and appropriate labelling, 
shipment and containment provisio ns are approved.  Samples can be shipped to specialist labs 
around the world and analysed by academic collaborators or commercial partners.  
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC0 0001
Version 4.0
Date 17 March 2020
57 (98)5.7.3 Chain of custody of biological samples 
A full chain o f custody  is maintained for all samples throughout their lifecycle.  
The PI at each site keeps full traceabilit y of collected bi ological  samples from  the pati ents 
while in storage at the study  site un til shipment or disposal (where appropriate) and keeps 
docum entati on of  receipt of arrival.  
The sample receiver keeps full traceabilit y of the sam ples while in storage and during use unt il 
used or disposed of or until further shipment and keeps documenta tion of  recei pt of  arrival.  
AZ keeps oversight of the ent ire life cycle through internal procedures, monitoring of study  
sites and audi ting of external laboratory  provi ders.  
Samples retained for further use are registered in the AZ bio bank during the e ntire life cycle.  
5.7.4 Withdrawal of informed consent for donated biological samples 
If a patient withdraws consent to the use of donated bio logical samples, the sam ples will  be 
disposed of/destroy ed, and the acti on documented.  If samples are already  analysed,AZ is not 
obliged to destroy  the resul ts of this research.  
As collect ion of donated bio logical samples is an opti onal part of  the study , the pati ent m ay 
continue in the study .
The PI:
 Ensures pat ients’ withdrawal of informed consent to the use of don ated 
samples is notified as soon as possible to AZ.
 Ensures that bio logical samples from that patient, if stored at the study  site, 
are identified as soon as possible, disposed of /destroy ed, and the action 
docum ented.
 Ensures the laboratory (ies) ho lding the samples is/are informed about the 
withdrawn consent as soon as possible and that samples are disposed 
of/destroy ed, the acti on docum ented and the signed document returned to 
the study  site.
 Ensures that the patient and AZ are informed about the sample d isposal.
AZ ensures the laboratory (ies) or bi obank hol ding the sam ples i s/are inform ed about the 
withdrawn consent as soon as possible and that samples are disposed of/destroy ed and the 
action docum ented and returned to the study  site.  
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
58 (98)6. SAFETY REPORTING A ND MEDICAL MANAGEMENT
The PI is responsible for ensuring that all personnel invo lved in the study  are f amiliar wi th the 
content of this sect ion.  
6.1 Definition of adverse events
An AE is the development of an undesirable medical condit ion or the deteri oration of a pre-
exist ing medical condit ion following or duri ng exposure to a pharmaceut ical product, whether 
or not considered causally related to the product.  An undesirable medical condit ion can be 
symptoms (e.g., nausea chest pain), signs (e.g., tachycardia , enlarged liver) or the abnormal 
resul ts of an invest igation (e.g., laboratory  findings, ECG).  In clinical studies, an AE can 
include an undesirable medical condit ion occurring at any  time, including run -in or washout 
periods, even if no study  treatm ent has been administered.  
The term  AE is used to include both serious and non -serious AEs.  The term AE in this 
docum ent refers only  to the categori es of  events described in Sect ion 6.3.  
6.2 Definitions of serious adverse event (SAE)
An SAE is an AE occurring during any study  phase (i .e., run -in, treatment, washout and fo llow-
up), that fulfils one or more of the fo llowing criteria:
 Results in death
 Is immediately life -threatening
 Requi res in -patienthospi talisat ionor prol ongat ion of exist ing
hospi talisat ion
 Results in persistent or significant disabilit y/incapacit y or substantial 
disrupt ion of the abilit y to conduct normal life functions
 Is a congenital abnormalit y or birth defect
 Is an important medical event that mayjeopardize the pati ent or m ay 
requi re medical intervention to prevent one of the outcomes listed above
For further guidance on the definit ion of a SAE, see Appendix Ato the Clinical Study  Protocol .  
6.3 Recording of adverse eve nts
6.3.1 Time period for collection of adverse events
AEs will be co llected fro mrando misat ion (visit 2) throughout the treatment period unt il and 
including the patient’s last study  visit.  
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
59 (98)SAEs will be recorded from the time of informed consent throughout the treatm ent peri od unt il 
and including the patient's last visit.  
AEs shoul d be recorded in the eCRF only if:
 It qualifies as an SAE (as defined in Sect ion 6.2)
 The AE is the reason for permanent discontinuat ionfrom IP (DAE )
 The AE is the reason for IP interruption or dose reduction
 It qualifies as an AE of interest
Volume deplet ion 
Renal events 
Major hypoglycaemic events
Fractures
Potenti al DKAs
AEs leading to amputation and AEs leading to a risk for lower li mb 
amputati ons (“preceding events”)
 A potential endpo int (see Secti on 5.1) fulfils the AE criteria. NB: not all 
potenti al endpoints are per definit ion an AE e.g., a potential endpoint 
solely related to laboratory  findings (see Section 6.3.7) should not be 
recorded unless any of the above ment ioned criteria is met. 
An AE/SAE could be associated with more than one potential endpo int. In such scenario, only  
one AE/SAE should be recorded but all potential endpo ints should be recorded individually.
6.3.2 Adverse even ts of interest
6.3.2.1 Volume depletion
Events of vo lume deplet ion (e.g., dehy dration, hypovol emia, or hy potensi on) will be recorded 
in the eCRF as AEs.  
6.3.2.2 Renal events
Renal events, such as an acute clinically relevant decline in kidney function as judged by  the 
investi gator , will be recorded in the eCRF as AEs. If the event also qualifies as a potential 
endpo int as defined in Section 5.1.3 .2, a separate eCRF will be co mpleted.
Clinical Stu dy Protocol
Drug Substance Dapagliflozi n
Study Code D169AC00001
Version 4.0
Date 17 March 2020
60 (98)6.3.2.3 Major hypoglycaemic events
A major hypoglyc aemic event is defined as an event that requires assistance of another person 
to actively  administer carbohydrates, glucagon, or take other corrective actions.
Plasma glucose concentrations may not be available during an event, but neurological recovery  
following the corrective act ions is considered sufficient evidence that the event was induced by 
a low pl asma gl ucose concentrati on.  Maj or hy poglycaemic episodes will be recorded in the 
eCRF as an AE and on an addit ional eCRF page.  
6.3.2.4 Fractures
All fractures will be recorded in the eCRF as AEs.
6.3.2.5 Diabetic ketoacidosis (DKA)
All potential events of DKA will be recorded in the eCRF and submitted to an independent 
DKA Adjudicat ion Co mmit tee (see Secti on 6.8.5 ).
6.3.2.6 Adverse events (AEs) leading to amputation and AEs leading to a risk for lower 
limb amputations (“preceding events”)
To ensure that data on amputations is systemat ically collected, am putati ons and underlying 
condi tions relevant to am putati on will be recorded on a specific eCRF page. The adverse event 
leading to amputation should be recorded in the eCRF as AE/SAE.
In addit ion, non- serious and seri ous events potentially  placing the pati ent at risk for a lower 
limb amputation (“preceding events”) should also be reco rded in the eCRF as AE/SAE, 
whether or not an amputation has taken place. The lower limb “preceding events” of interest 
include diabet ic foot rel ated condi tions, vascular, wounds/injury/trauma, infect ion and 
neuropathy . If any of these or other potentially relevant event have occurred, relevant 
inform ation must be provided (this will be co llected on a dedicated eCRF page -for details see 
eCRF instruction).
6.3.3 Follow -up of unresolved adverse events
Any AEs that are unresolved at the patient’s last study  visit in the study are fo llowed up by the 
investigator for as long as medically indicated, but without further recording in the CRF.  AZ 
retains the right to request additional informat ion for any pat ient with ongoing AE(s)/SAE(s) at 
the end of the study , if judged necessary .  
6.3.4 Variables 
The fo llowing variables will be collect for each AE:
 AE (verbat im)
 The date when the AE started and stopped
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
61 (98) Maximum intensit y (mild/m oderate/severe)
 Whether the AE is serious or not
 Invest igator causalit y rating against the IP ( yes or no)
 Action taken with regard to IP
 Outcom e
In addit ion, the fo llowing vari ables will be collected for SAEs:
 Date AE m et cri teria for seri ous AE
 Date invest igator became aware of serious AE
 AE is seri ous due to
 Date of hospi talisat ion
 Date of dischar ge
 Probable cause of death
 Date of death
 Autopsy  performed
 Causalit y assessment in relat ion to Study  procedure(s) and/or other 
medicat ion
 Descript ion of AE
It is important to dist inguish between serious and severe AEs.  Severit y is a measure of 
intensity whereas seriousness is defined by the criteria described in Sect ion 6.2. An AE of 
severe intensit y need not necessarily be considered serious. For example, nausea that persists 
for several  hours may  be considered severe nausea, but not a SAE unless it meets the criteria 
shown in Section 6.2. On the other hand, a stroke that results in only  a limi ted degree of 
disabili ty may be considered a mild stroke but would be a SAE when it satisfies the criteria 
shown in Section 6.2.  
6.3.5 Causality collection
The invest igator will assess causal relat ionship between IP and each AE, and answer ‘yes’ or 
‘no’ to the question ‘Do y ou consi der tha t there i s a reasonable possibilit y that the event may  
have been caused by the IP?’
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
62 (98)For SAEs causal relationship will also be assessed for other medicat ion and study  procedures.  
Note that for SAEs that could be associated with any  study  procedure the caus al relati onship is 
implied as ‘yes’.  
A guide to the interpretation of the causalit y quest ion is found in Appendix A.
6.3.6 Adverse events based on signs and symptoms
All AEs spontaneously reported by  the pati ent, or reported in respon se to the open question 
from the site personnel : ‘Have you had any health problems since the previous visit/you w ere 
last asked?’ , or revealed by observat ion, will be collected and recorded in the eCRF (if 
fulfilling the criteria for recording as specified in Section 6.3.1 ). When collect ing AEs, the 
recording of diagnoses is preferred (when possible) to recording a list of signs and symptoms.  
However, if a diagnosis is known and there are other signs or symptoms that are not generally 
part of the diagnosis, the diagnosis and each sign or symptom will be recorded separately.  
6.3.7 Adverse events based on examinations and tests
The results from protocol mandated laboratory  tests and vi tal signs will be summarised in the 
CSR. Deteri oration as com pared wi th baseline in protocol -mandated l aboratory  values or vital 
signs shoul d therefore only  be reported as AEs if they fulfil any of the SAE criteria or are the 
reason for discont inuat ion of treatment with the investigational product. 
If deteri oration in a laboratory  value/vi tal sign i s associ ated wi th clinical signs and symptoms, 
the sign or symptom  will be reported as an AE and the associated laboratory  resul t/vital sign 
will be considered as addit ional informat ion.  Wherever possible the reporti ng invest igator uses 
the clinical, rather than the laboratory  term  (e.g., anaemia versus low Hb value).  In the absence 
of clinical signs or symptoms, clinically  relevant deteri orations in non -mandated parameters 
shoul d be reported as AE(s).  
6.4 Repor ting of serious adverse events (SAEs)
All SAEs have to be reported, whether or not considered causally related to the IP, or to the 
study  procedure(s).  All SAEs will be recorded in the eCRF.  
If any SAE occurs in the course of the study, then Invest igato rs or other site personnel inform 
the appropriate AZ representatives within one day  i.e., immediately  but no later than 24 hours 
of when he or she beco mes aware of it.  
The designated AZ representative works with the investigator to ensure that all the n ecessary  
inform ation is provided to the AZ Patient Safet y data entry  site within 1 calendar day of initial 
recei pt for fatal and life threatening events and within 5 calendar days of initial receipt for all 
other SAEs.  
For fatal  or life -threatening AEs w here important or relevant informat ion is missing, active 
follow
-up is undertaken immediately .  Investi gators or other site personnel inform AZ 
Clinical Stu dy Protocol
Drug Substance Dapa gliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
63 (98)representatives of any  follow-up inform ation on a previously reported SAE within one calendar 
day i.e., immediat ely but no later than 24 hours of when he or she beco mes aware of it.  
Once the Invest igators or other site personnel indicate an AE is serious in the WBDC system, 
an autom ated email alert is sent to the designated AZ representative.  
If the WBDC system is not available, then the investigator or other site personnel reports a SAE 
to the appropriate AZ representative by telephone in accordance wit h SAE reporting t imelines.  
The AZ representative will advise the invest igator/site personnel how to proceed. 
6.4.1 Reporting of serious adverse events (SAEs) considered to be potential endpoints
In order to avoid unnecessary  unblinding of efficacy  endpoint events, certain SAEs which are 
also potential endpo ints (i.e., fatal events and heart failure events) will not b e reported to health 
authori ties.  Clinical data for the above ment ioned events will be recorded as AEs/SAEs as well 
as on separate event forms in the eCRF.  Recording of a suspected endpoint should be done 
within the same t imeframes as defined for SAEs (s ee Secti on 6.4).  
In addit ion, fatal  AEs and potential heart failure endpoints will be centrally  adjudicated by  an 
independent CEA committee (see Section 5.1.1 and 6.8.4). If adjudicat ion confirms the 
endpo int, the SAE will not be reported to health authorities. However, if it is determined by  the 
CEA co mmit tee that a potenti al endpoint in the above ment ioned categories doe s not meet the 
endpo int criteria, the event will be reported (according to the timelines specified in Section
6.3.1 ) to AZ patient safet y data entry  site and if applicable to the healt h authorit ies (note that 
the clock starts w hen the adjudicat ion results are available).
6.5 Overdose
Dapagliflozin has been well tolerated at doses of up to 500 mg/day in single dose testing in 
healt hy vo lunteers and up to 100 mg/day in repeat dose testing for 14 days in healt hy 
volunteers and patients with T2D.  Suspected single intake of more than 50 tablets of  10mg 
dapagliflozin tablets or repeated intake of more than 10 tablets of  10mg dapagliflozin tablets 
shoul d be recorded in the eCRF.  If an overdose is suspected, monitoring of vital funct ionsas 
well as treatment should be performed as appropriate.  
For further information regarding overdose, refer to the IB.
 An overdose with associated AEs is recorded as the AE 
diagnosis/symptom s on the rel evant AE m odules in the eCRF and on the 
Overdose eCR F module.  
 An overdose without associated symptoms is only  recorded in the 
Overdose eCRF module.  
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
64 (98)If an overdose on an AZ study  drug occurs in the course of the study , then the invest igator or 
other si te personnel inform appropriate AZ representatives im mediately, or no later than 
24hours of when he or she beco mes aware of it.  
The designated AZ representative works with the investigator to ensure that all relevant 
inform ation is provided to the AZ Patient Safet y data entry  site.  
For overdoses associa ted wi th a SAE, the standard reporting t imelines apply (see Section 6.4).  
For other overdoses, reporting must occur within 30 days.  
6.6 Pregnancy
All pregnancies and outcomes of pregnancy should be reported to AZ .  
6.6.1 Maternal exposure
If a patient becomes pregnant during the course of the study  IP shoul d be discont inued 
immediately .  
Pregnancy itself is not regarded as an AE unless there is a suspicio n that the IP under study  
may have interfered with the effect iveness of a contraceptive medicat ion. Congenital 
abnorm alities/birth defects and spontaneous miscarriages should be reported and handled as 
SAEs. Elective abortions wit hout complicat ions should not be handled as AEs.  The outcome of 
all pregnancies (spontane ous miscarri age, el ective termination, ectopic pregnancy, normal birth 
or congenital abnormalit y) shoul d be f ollowed up and docum ented even if the pat ient was 
discontinued fro m the study .  
If any pregnancy  occurs during the course of the study , then the i nvestigator or other site 
personnel informs the appropriate AZ representatives within 1 day i.e., immediately  but no 
later than 24 hours of when he or she becom es aware of i t.  
The designated AZ representative works with the investigator to ensure that al l relevant 
inform ation is provided to the AZ Patient Safet y data entry  site wi thin 1 or 5 calendar days for 
SAEs (see Section 6.4) and wi thin 30 days for all other pregnancies.  
The same timelines apply when ou tcom e inform ation is available.  
The PREGREP module in the eCRF is used to report the pregnancy and the PREGOUT paper 
CRF form is used to report the outcome of the pregnancy.  
6.7 Management of IP related toxicities (not applicable)
6.8 Study governance and over sight
6.8.1 Executive Committee
Together with AZ the Execut ive Co mmit tee will  be responsible for the final overall study  
design, including the development of the study  protocol  and eCRF, and any  protocol  
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
65 (98)amendments, supervisio n of the study  conduct and progress, development of any protocol 
amendments needed during the study , liaison wit h the CEA Committee and DMC, as needed, 
development of the statist ical analysis plan (SAP), interpretation of the final data and reporting 
(presentations at internat ional congresse s and publications in peer reviewed journals) o f the 
study .  
The Execut ive Co mmittee will make recommendatio ns to AZ with regard to early stopping or 
modificati ons of  the study  based on the information received from the DMC.  The Execut ive 
Committee will be co mprised of designated international academic leaders and non -voting 
members of the Sponsor, and will operate under an Executive Co mmittee charter.  
6.8.2 National Lead Investigator (NLI) Committee
The National Lead Investigator (NLI) Committee will be co mprised of NLIs from each country  
where the study  is conducted and supervised by  the Executive Committee.  Members of the 
committee will be responsible for providing clinical guidance on study implementation, 
recrui tment and study  conduct in their respect ivecountry .  
6.8.3 Data Monitoring Committee (DMC)
An independent DMC will be appo inted and will report to the Executive Co mmittee.  The 
DMC will be responsible for safeguarding the interests of the patients in the study by assessing 
the safet y of the IP during t he study, and for reviewing the overall conduct of the study.  The 
DMC will have access to the individual treatment codes and be able to merge these with the 
collected study  data while the study  is ongoing.  A DMC charter will be prepared to detail 
preci seroles and responsibilit ies and procedures to ensure maintenance of the blinding and 
integrity of the study  in the review o f accumulat ing data and interactions wit h the Executive 
Committee.  
6.8.4 Clinical Event Adjudication (CEA) Committee
The rol e of the CEA commit tee is to independent ly review, interpret and adjudicate potential 
endpo ints that are experienced by the pat ients.  Endpoints will be ident ified preliminary by the 
Invest igators, and also by AZ personnel or in the CEA process as specified in the CEA charter.  
The CEA co mmittee members will not have access to individual treatment codes for any 
patient or clinical efficacy endpoint and safet y event.  The preci se responsibilit ies and 
procedures applicable for CEA will be detailed in the CEA charter.  
6.8.5 Diabetic Ketoacidosis Adjudication Committee T2D
All potential events of DKA will be submitted to an independent DKA Adjudicat ion 
Committee.  The committee will be kept blinded to the treatment codes.  A separate DKA 
Adjudicat ion Manual will define and desc ribe the procedures for the collection of DKA 
inform ation, handling, adjudicat ion criteria and reporti ng of these events.
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
66 (98)6.9 Medication Error
For the purposes of this clinical study  a medicat ion error is an unintended failure or mistake in 
the treatment proce ss for an AstraZeneca study  drug that ei ther causes harm to the subject or 
has the potential to cause harm to the subject. 
A medicat ion error is not lack of efficacy o f the drug, but rather a human or process related 
failure while the drug is in control o f the study  site staff or subj ect.
Medicat ion error includes situat ions where an error 
occurred
was i dentified and intercepted before the subject received the drug
did not occur, but circumstances were recognized that could have led to an error
Examples o f events to be reported in clinical studies as medication errors:
Drug name confusio n
Dispensing error e.g. medicat ion prepared incorrectly, even if it was not actually given 
to the subject
Drug not administered as indicated, for example, wrong route or wr ong si te of 
administration
Drug not taken as indicated e.g. tablet disso lved in water when it should be taken as a 
solid tablet 
Drug not stored as instructed e.g. kept in the fridge when it should be at room 
temperature 
Wrong subject received the medicat ion (excluding IVRS/IWRS errors)
Wrong drug administered to subject (excluding IVRS/IWRS errors)
Examples of events that do not require reporting as medicat ion errors in clinical studies:
Errors related to or resulting fro m IVRS/IWRS -including those whi ch lead to one of 
the above listed events that would otherwise have been a medicat ion error 
Subject accidentally missed drug dose(s) e.g. forgot to take medicat ion
Accidental  overdose (will be captured as an overdose)
Subject failed to return unused medic ation or em pty packaging
Errors related to background and rescue medicat ion, or standard of care medicat ion in 
open l abel studi es, even if an AZ product 
Medicat ion errors are not regarded as AEs but AEs may  occur as a consequence of the 
medicat ion error. 
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
67 (98)If a medicat ion error occurs in the course of the study , then the Invest igator or other site 
personnel informs the appropriate AstraZeneca representatives within 1 day i.e., immediately 
but no later than 24 hours of when he or she becomes aware of it.
The designated AstraZeneca representative works with the Invest igator to ensure that all 
relevant informat ion is completed wi thin 1 or 5 calendar days if there is an SAE associated with 
the medicat ion error (see Section 6.4) and wi thin 30 day s for all other m edicat ion errors.
7. INVESTIGATIONAL PROD UCT (IP) AND OTHER 
TREATMENTS
7.1 Identity of investigational product (IP)
Investigational product (IP) Dosage form and strength Manufacturer
Dapagliflozin 10 mg Green, plain, diamond shaped, 
film coated tablets 10 mgAZ
Matching placebo for 
Dapagliflozin 10 mgGreen, plain, diamond shaped, 
film coated tablets placeboAZ
Dapagliflozin 5 mg Green, plain, diamond shaped, 
film coated tablets 5 mgAZ
Matching placebo for 
Dapagli flozin 5 mgGreen, plain, diamond shaped, 
film coated tablets placeboAZ
Dapagliflozin and its matching placebo tablets will be packed in bottles.  The tablets may 
contain lactose, which may cause disco mfort in lactose -intolerant individuals.
7.2 Dose and tre atment regimens
At randomisat ion, visit 2 (day 0), eligible pat ients will be rando mly assigned to 1 of2 
treatm ents:
 Dapagliflozin 10 mg, given once daily per oral use
 Placebo –one pl acebo tabl et to m atch dapagliflozin 10 mg, given once 
daily  per oral  use
Randomisat ion and treatment pack assignment will be managed via an IxRS at visit 2.  The IP 
shoul d be taken per oral once daily  in the m orning and at approximately the same time every  
day, during the study  period.  If the pati ent, f or any reason prefers n ot to administer the IP in 
the morning, any other time point during the day  may be applied, provided the patient routinely 
administer the IP in approximate 24 hours intervals.  The IP should not be altered (e.g., 
crushed, put in another vehicle) and should not be given by  nasogastri c tube or other routes.
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
68 (98)If the dose is adjusted (i.e., lowered to 5 mg or increased back to 10 mg) during the study  (see 
Secti on 3.9.1 and 3.9.2 ), this will be handled in IxRS and the dose change will be recorded in 
the eCRF.
Missed doses of dapagliflo zin or pl acebo blinded study  medicati on shoul d not be com pensated 
for (i.e., if a dose is missed, the next regularly  schedul ed dose shoul d be t aken and should not 
be doubled).
7.3 Labelling
Labels will be prepared in accordance wit h Good Manufacturing Practice (GMP) and local 
regul atory  guidelines.  The l abels will fulfil GMP Annex 13 requi rements for labelling.  Label 
text will be translated into lo cal language.  
7.4 Storage
All IPs should be kept in a secure place under appropriate storage condit ions.  The IP label on 
the bottle specifies the appropriate storage.  
7.5 Compliance
The administration of all IPs should be recorded in the appropri ate secti ons of theeCRF.
7.6 Accountability
The study  drug provi ded for thi s study  will be used only as directed.  
The study  personnel will account for all study  drugs di spensed to and returned fro m the pati ent.  
Patients will  be asked to bring all unused IP and empt y packages to the study  site at all visi ts.  
The invest igator or delegate will record the amount of returned tablets in the eCRF.  Any 
patient found to be noncom pliant woul d be counselled on the importance of taking their IP as 
prescribed.
Any IP deliberately or acci dentally  destroy ed must be recorded.  Any  discrepancy  between 
dispensed and returned IP should be explained.
The invest igator will retain the returned medicat ion unt il the AZ representative or delegate 
collects it, along with any medicat ion not di spensed.  The AZ representative or delegate is 
responsible for confirming that the invest igator or delegate has recorded the quantit ies of 
returned and unused tablets at a patient level before medicat ion is destroyed.  The AZ 
representative or delegate will advise on the appropriate method for destruction of unused IP.
7.7 Concomitant and other treatments 
All patients should be treated according to regional standards of care for CV risk factors (e.g., 
BP, lipids, and ant ithrombotic treatment), diabetes and CKD complications (e.g., 
hyperphosphatemia, hyperparathy roidism , hyperkalaemia, aci dosis and renal anaemia).
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
69 (98)Background medicat ion will not be provided by the Sponsor.
7.7.1 Restricted medication
Treatment with non -steroi dal ant i-inflammatory drugs (NSAID) should, i f possible, be avoided 
during the study .
7.7.2 Prohibited medication
Concomitant treatm ent (i.e., treatm ent in combinatio n with IP) wi thopen l abel SGLT2 
inhibitors e.g., dapagliflozin, empaglifl ozin,canagliflo zin, ertugliflozin, tofogliflo zin and 
luseogliflozi n and fix dose combinat ions containing these drugs is prohibited.  Also in 
situations when the patient is not on IP, treatment with open label SGLT2 inhibitors during the 
study , coul d interfere wi th the interpretation of study  resul ts and shoul d therefore not be given 
unless all other possibilit ies to treat the patient properly has been considered.   
7.7.3 Recording of concomitant treatment
Detailed recording o f medications rel ated to CKD (see Section 7.7.4), diabetes (see Section 
7.7.5) as well as other relevant cardi ovascular medicat ions (e.g., statins, ant ihypertensive and 
antithrombotic agents) will be made throughout the study . In addi tion, concomitant medicat ions 
will be recorded at the time of any SAEs, poten tial endpo ints and AEs of interest (as defined in
Secti on 6.3). Recording of other concomitant medications will be made at randomisation 
(visit 2) and at SCV.
7.7.4 Chronic kidney disease (CKD) medications
To be eligible, the patient needs to be on stable and for th e pati ent m aximum tol erated l abelled 
daily  dose of ACE -I or ARB for at least 4 weeks before visit 1, if not medically 
contraindicated.  If the patient is not on an ACE -I or ARB at the time o f enrolment the reason 
will be recorded in the eCRF.
Details regar ding the fo llowing CKD related treatments will be recorded in the eCRF 
throughout the study :
 RAAS inhibit ion: ACE -I/ARBs, renin inhibitors, mineralocortico id 
antagonists
 Diuretics: Loop diuretics, thiazide diuret ics and other diuret ics
 Treatment of underly ing ki dney disease: cytotoxi c agents, 
immunosuppressive agents, other immunotherapy
 Phosphate binders
 Potassi um binders 
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
70 (98)7.7.5 Anti- diabetes treatment of patients with established diagnosis of type 2 diabetes 
(T2D)
Patients wi th T2D at randomisat ion in this stud y will cont inue their T2D treatment.  Treatment 
shoul d be based on established guidelines and according to local laboratory  values.  Pati ents are 
eligible for adjust ments in their ant i-diabetes treatment at the discret ion of their diabetes healt h 
care prov ider.  Diabetes medicat ions at baseline and any  changes throughout the study , will be 
recorded in the eCRF.  
7.7.5.1 Use of medications known to cause hypoglycaemia in type 2diabetes (T2D) 
patients 
Insulin and insulin secretagogues are known to cause hypoglycae mia.  Therefore, pati ents 
treated with insulin or sulfo nylurea (SU) have a higher risk of experiencing hypoglycaemic
events compared wit h those treated with other antidiabet ic agents.  Therefore a lower dose of 
insulin or insulin secretagogues may be requi red to minimize the risk o fhypoglycaemia when 
used in co mbination wit h study  medicat ion.
Reduction o f insulin by 10 to20% (total daily dose) and SU by 25 to50% and increased 
frequency  of blood gl ucose m onitoring may  be consi dered in pati ents receiving i nsulin and/or 
SU and with baseline HbA1c ≤7% at randomisat ion.
7.7.6 Other concomitant treatment
Medicat ions other than described above, which is considered necessary for the patient’s safet y 
and wellbeing, may be given at the discret ion of the invest igator and recorded in the 
appropriate sections of the eCRF, as applicable.  
7.8 Post Study Access to Study Treatment
Post
-study treatment will not be provided by the Sponsor .  
8. STATISTICAL ANALYSES BY ASTRAZENECA (AZ)
8.1 Statistical considerations
All personnel invo lved w ith the analysis o f the study  will remain blinded unt il database lock 
and protocol vio lations have been ident ified and documented.  
A co mprehensive SAP will be developed prior to first randomised patient and any subsequent 
amendments will be documented, w ith final amendments completed prior to unblinding of the 
data.
The results of the key  study  outcom e will be independent ly validated by  an external  statist ical 
team .  
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
71 (98)8.2 Sample size estimate
The primary  object ive of the study  is to determine the superiorit y of dapagliflo zin versus 
placebo in reducing the incidence of the primary  com posite endpoint.  Assuming a true hazard 
ratio of 0.78 between dapagliflozin and placebo, using a one -sided alpha of 2.5%, 681 primary  
endpo ints will provide a statist ical power of 90% for the test of the primary  com posite 
endpo int.  Thi s is based on an overall 1:1 allocat ion between dapagliflozin and placebo.  The 
study  is event -driven.  The assumed hazard ratio of 0.78 is considered as clinically relevant and 
has taken into accoun t the renal outcomes in the EMPA -REG tri al.  
With an annual event rate of 7.5% in the placebo treatment group, 4000 patients are estimated 
to provi de the requi red number of primary  events, based on an anticipated recruit ment period of  
24 m onths and an ave rage fo llow-up peri od of  approximately  33 m onths.  The assumed placebo 
event rate of 7.5% is based on a review of published data in the CKD populat ion.In addit ion, 
the expected number of patients who will be lost to fo llow-up is expected to be small; hence, 
they are not consi dered in the determinat ion of the sample size.  
8.3 Definitions of analysis sets
8.3.1 Full analysis set (FAS)
All patients who have been randomised to study  treatm ent will be included in the full analysis 
set (FAS) irrespect ive of their pr otocol adherence and cont inued participat ion in the study .  
Patients will  beanalysed according to their randomised IP assignment, i rrespect ive of the 
treatm ent actually received.  The FAS will be considered the primary  analysis set for the 
primary  and sec onda ry variables and for the exploratory  efficacy variables.  
8.3.2 Safety analysis set
All patients who receive at least one dose of randomised treatm ent will be included in the 
safet y popul ation.  Patients will be analysed according to the treatment actually  received.  The 
Safety analysis set will be considered the primar y analysis set for all safet y variables.
8.4 Outcome measures for analyses
8.4.1 Primary outcome measure 
The primary  outcom e measures are detailed in Section 2.1.  
8.4.2 Secondary outcome measure
The secondary  outcome m easure s are detailed in Section 2.2.
8.4.3 Safety outcome measure
The safet y outcom e measures are detailed in Sect ion 2.3.  
8.4.4 Exploratory outcome measure
The exploratory  outcom e measures are detailed in Section 2.4.  
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
72 (98)8.5 Methods for statistical analyses
8.5.1 Hypotheses
For the primary  endpoint the following hypothesis will be tested at the 2.5% 1-sided level:
H0: HR [dapagliflozin:placebo] ≥1
Versus
H1: HR [dapagliflozin:placebo] <1
8.5.2 Closed testing procedure
A closed testing procedure including a pre -specified hiera rchical  ordering of the primary  and 
secondary  endpoints will  be utilized.  The Ty pe I error will b e controlled at a one -sided 
0.025 level for mult iplicit y across primary  and secondary  endpoints .  Stat istical significance 
will be assessed in the pre -specified order of the endpoints as specified in Sect ion 2.1and 2.2.  
The testing procedure will cont inue down the hierarchy if the preceding endpo int is rejected at 
a one -sided 0. 025level and will stop if the preceding endpo int is not rej ected at a one -sided 
0.025 level.  Expl oratory  endpoints will  be tested at a one -sided 0.025 level without adjust ment 
for multiplicity.
8.5.3 Analysis of the primary variable (s)
The primary  variable is the time to first event included in the primary  com posite endpoint.  The 
primary  analysis will be based on the intention to treat (ITT) principle using the FAS.  
In the analysis of the primary  com posite endpoint, treatm ents (dapagliflozin versus placebo) 
will be co mpared using a Cox proportional hazards model wit h a factor for treatment group , 
stratified by randomisat ionstratificat ion factors (T2D, UACR), and adjust ing for eGFR . In 
general, the analysis will use each pat ient's last contact as the censoring date for patients 
without any  primary events.  The p -value, hazard ratio (HR) and 95% confidence interval will 
be reported.
The contribut ion of each component of the primary co mposite endpo int to the overall treatment 
effect will be examined .  Methods similar to those described for the primary analysis will be 
used to separately analyse thetime fro mrando misationto the first occurrence of each 
component of the primary  com posite endpo int.  Last contact will be treated as the censoring 
date for patients without the endpoint of interest.  Hazard rati os (HR) and 95% confidence 
intervals will b e reported.
Kaplan -Meier estimates of the cumulat ive incidence to the first occurrence of any event in the 
primary  endpoint will be calculated and plotted, for overall analysis and for the individual 
components.  
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
73 (98)8.5.4 Analysis of the secondary variables
The se condary  variables will be analysed in the similar manner as the primary  variable.  
8.5.5 Subgro up analysis
Subgroup variables for the primary  efficacy  endpoint and secondary  efficacy endpoints include 
demography , baseline disease characteristics, baseline conco mitant m edicati ons and others.
Cox proportional hazards models will be performed to examin e treatm ent effects wi thin 
relevant subgroups separately.  The p- values for the subgroup analyses will not be adjusted for 
multiple comparisons as the tests are explo ratory  and will be interpreted descript ively.  Event 
rates by  treatm ent and HRs wit h 95% c onfidence intervals will be reported for each subgroup .  
HRs and CIs for overall analysis and subgroups will be presented with forest plots.  Further 
details o f the subgroup analysis, including the list of subgroup variables, will be provided in the 
SAP.
8.5.6 Interim analysis
Not a
pplicable.
8.5.7 Sensitivity analysis
Details o f the sensit ivity analysis will be provided in the SAP.  
8.5.8 Analysis of safety variables
The number and p ercent of patients with SAEs, DAEs, AEs leading to dose reductions and 
temporary  interrupti ons, AEs of interest, will be summarized by treatment group.  Changes in 
clinical chemistry /haematol ogyparam eters will  be summarized over time by treatment group.  
In addit ion, the number and percent of patients with a marked abnormalit y in clinical laboratory  
tests will be summarized over time by treatment group.  For safet y analyses, summaries will be 
provi ded using both on treatment observations and using all obse rvations regardless of whether 
patients are on or off study  treatm ent.  
8.5.9 Exploratory analysis
The exploratory  variables (excluding PK and bio markers for future exploratory  research) will 
beanalysed as specified in the SAP.  
9. STUDY AND DATA MANAG EMENT BY A STRAZENECA (AZ)
9.1 Training of study site personnel
Before the first patient is entered into the study , an AZ representative will review and discuss 
the requirements of th e Clinical Study  Protocol  and rel ated docum ents wi th the si te personnel 
and also train t hem in any  study  specific procedures and the WBDC, ePROs system and other 
relevant sy stems utilised.  
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
74 (98)The PI will ensure that appropriate training relevant to the stud y is given to all site personnel, 
and that any  new informat ion relevant to the performan ce of this study  is forwarded to the 
personnel invo lved.  
The PI will maintain a record of all individuals involved in the study  (medical, nursing and 
other personnel) .  
9.2 Monitoring of the study
During the study , an AZ representative will have regular con tacts with the study  site, including 
visits to:
 Provi de inform ation and support to the invest igator(s) and site personnel.
 Confirm that facilit ies remain acceptable.
 Confirm that the invest igational team  is adhering to the protocol; that data 
are being acc urately and timely recorded in the eCRFs; that bio logical 
samples are handled in accordance with the Laboratory  Manual and that 
study  drug accountabilit y checks are bei ng performed.
 Perform  source data verification (a comparison of the data in the eCRFs 
with the patient’s medical records at the hospital or practice, and other 
records relevant to the study ) incl uding verificati on of  informed consent of 
participat ing patie nts.  Thi s will require direct access to all original records 
for each pat ient (e.g., medical records).
 Perform  source data revi ew, i .e., review of source documentation to check 
qualit y of source, revi ew protocol  com pliance, ensure crit ical processes 
and s ource docum entati on are adequate.
 Ensure withdrawal of informed consent to the use of th epatient’s 
biological  samples is reported and biological samples are identified and 
disposed of/destroyed accordingly , and the acti on is docum ented, and 
reported to th e pati ent.
The AZ representative will be available between visits if the invest igator(s) or other personnel 
at the study  site needs inform ation and advice about the study  conduct.
9.2.1 Risk based quality management
Qualit y by desi gn will  be implemented, includi ng a focus on ident ifying key risks to patient 
safet y, data qualit y, and Good Clinical P ractice (GCP)/regulatory co mpliance, to build qualit y 
into the desi gn, conduct, analysis and reporting of the study .  
A risk based monitoring approach will be applied for this study .  This includes a mix of 
monitoring strategi es: on -site monitoring, remot emonitoring (site l evel monitoring act ivities 
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
75 (98)perform ed at a l ocati on other than the study  site) and centralized m onitoring.  Moni toring 
strategies will be tailored to consider risks, permit timely oversight (through central/remote 
monitoring and use of te chno logy), and will be focused on crit ical processes and crit ical data.  
Central  monitoring will be used to check that data is consistent and complete, ident ify unusu al 
distribut ion of data, identify higher risk sites to target additional mo nitoring, and to ensure 
routi ne review of data is completed in real t ime.
9.2.2 Source data
Refer to the CSA for location of source data.  The investigator must provide direct access to 
source data/documents for monitoring, audits, (institut ional review board/independent eth ics 
committee) IRB/IEC review, and regulatory  inspecti ons.
9.2.3 Study agreements
The PI at each/the study  site shoul d com ply wi th all the term s, condi tions, and obligat ions of 
the CSA, or equivalent, for this study .  In the event of any  inconsistency between th is Clinical 
Study  Protocol  and the CSA, the terms of Clinical Study  Protocol  shall  prevail  with respect to 
the conduct of the study  and the treatm ent of patients and in all other respects, not rel ating to 
study  conduct or treatm ent of pati ents, the term s ofthe CSA shall prevail.  
Agreements between AZ and the PI should be in place before any study  related procedures can 
take pl ace, or patients are enrolled.  
9.2.4 Archiving of study documents
The invest igator follows the principles outlined in the CSA.  
9.3 Study timetable and end of study
The end o f the study  is defined as ‘the l ast vi sit of the last pati ent undergoing the study ’.  
The study  is expected to start in Q1 2017 an d to end by  Q42020.
The study  may be terminated at individual study  sites if the study  procedures are not being 
perform ed according to GCP, or if recruit ment is slow.  AZ may also terminate the ent ire study  
prem aturely  if concerns for safet y arise wi thin this study  or in any  other study  with 
dapagliflozin.
9.4 Data management by AstraZeneca (AZ)
Data m anagement will be performed by IQVIA Ltd , according to the Data Management Plan 
(DMP) .
Data entered into the eCRF will be immediately saved to a central databas e and changes 
tracked to provide an audit trail.  The data will then be reviewed, querie dand updated as 
needed.
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
76 (98)AEs and medical/surgical history  will be classified according to the termino logy of the l atest 
versio n the Medical Dictionary  for Regul atory  Activities (MedDRA).  Medications will be 
classified according to the WHO Drug Dictionary.Classificati on coding will be performed by
the Medi cal Coding Team at the IQVIA Ltd.  
The data will be validated as defined in the DMP.  Qualit y control  procedures w ill be applied to 
each stage of data handling to ensure that all data are reliable and h ave been processed 
correctly .  The DMP will also cl arify the rol es and responsibilit ies of the various funct ions and 
personnel invo lved in the data management process.
When all data have been coded, validated, signed and locked, clean file will be declared .  Any 
treatm ent revealing data may  thereafter be added and the final database will be locked.  
Serious adverse event (SAE) Reconciliation
SAE reconciliat ion will be done between the study database and safet y database.  
10. ETHICAL AND REGULATO RY REQUIREMENT S
10.1 Ethical conduct of the study
The study  will be perform ed in accordance with ethical principles that have their origin in the 
Declaration of Helsinki and are consisten t with Internat ional Conference on Harmonisat ion 
(ICH)/GCP, applicable regulatory  requi rements and the AZ policy on Bioethics and Human 
Biological Samples.  
10.2 Subject data protection
The ICF will incorporate (or, in so me cases, be accompanied by a separate document 
incorporating) wording that complies with relevant data protection and privacy legislat ion.  
10.3 Ethics and regulatory review
An IRB/IEC should approve the final study  protocol , including the final versio
n of the ICF and 
any other written informat ionand/or m aterials to be provided to the patients.  The investigator 
will ensure the dist ribution of these documents to the applicable IRB/IEC, and to the site 
personnel.  
The opinio n of the IRB/IEC should be given in writing.  The invest igator should subm it the 
written approval  to AZ before enro lment of any patient into the study.
The IRB/IE Cshoul d approve all advertising used to recruit patients for the study .  
AZ should approve any  modificati ons to the ICF that are needed to meet local requirements.  
If required by  local regulat ions, the protocol should be re -approved by the IRB/IEC annu ally.  
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
77 (98)Before enrolment of any patient into the study , the final  study  protocol , incl uding the final 
versio n of the ICF, is approved by  the nat ional regulatory  authori ty or a notification to the 
national regulatory  authori ty is done, according to local re gulati ons.  
AZ will handle the distribut ion of any of these documents to the nat ional regulatory  authori ties.  
AZ will provide Regulatory  Authori ties, IRB/IECs and PI s with safet y updates/reports 
according to local requirements.  
10.4 Informed consent
The PI at each site will:
 Ensure each patient is given full and adequate oral and written informat ion 
about the nature, purpose, possible risk and benefit  of the study .
 Ensur e each patient is notified that they  are f ree to di scontinue fro m the 
study  at any  time.
 Ensure that each patient is given the opportunit y to ask questions and 
allowed time to consider the informat ion provi ded.
 Ensure each patient provides signed and dated informed consent before 
conducting any  procedure specifically for the study .
 Ensure the original, signed ICF(s) is/are stored in the Invest igator’s Study  
File.
 Ensure a copy  of the signed ICF is given to the patient.
 Ensure that any  incentives for patient s who participate in the study  as well  
as any provisio ns for pati ents harm ed as a conseq uence of study  
participat ion are described in the ICF that is approved by an IRB/IEC.  
10.5 Changes to the protocol and informed consent form (ICF)
Study  procedures will no t be changed without the mutual agreement of the International 
Coordinat ing Investigator and AZ.  
If there are any substant ial changes to the study  protocol , then these changes will be 
implemented in a new versio n of the protocol.
The new versio n of the s tudy protocol  is to be approved by  the relevant IRB/IEC and if 
applicable, also the nat ional regulatory  authori ty, before implementati on.  Local  requi rements 
are to be fo llowed for new versio n protocols.  
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
78 (98)AZ will distribute any subsequent new versio ns of the protocol to each PI.  For distribut ion to 
IRB/IEC see Section 10.3.  
If a new version o f the protocol requires a change of a study  sites’ ICF, AZ and the study  site’s 
IRB/IEC are to approve the revised ICF before the revised form is used.
10.6 Audits and inspections
Authori sed representatives o f AZ,a regulatory  authori ty, or an IRB/IEC may  perform audi ts or 
inspections at the study  site, including source data verification.  The purpose of an audit or 
inspection is to sy stem atically and independent ly examine all study related activit ies and 
docum ents, to determine whether these activit ies were conducted, and data were recorded, 
analysed, and accurately reported according to the protocol, GCP, guidelines of the ICH , and 
any applicable regulatory  requi rements.  The investi gator will contact AZ immediat ely if 
contacted by  a regul atory  agency  about an inspect ion at the study  site.  
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
79 (98)11. LIST OF REFERENCES
Baker et al 2015
Baker WL, Smyth LR, Rich DM, Bourret EM, Chamberli n KW, White WB.  Effects of sodium -glucose 
co-transporter 2 inhibitors on BP: A systemat ic review and meta -analysis. J Am Soc Hypertens 2014; 8 
(4): 262 -275.  
Barnett et al 2014
Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle H, et al, on be half of EMPA -REG 
RENAL trial investigators. Efficacy and safety of empagliflozin added t oexisting antidiabetics 
treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double -blind, 
placebo -controlled trial. Lancet Diabetes En docrinol 2014; 2(5): 369- 384. 
Bays et al 2013
Bays HE, Weinstein R, Law G, Canovatchel W.    Canagliflozin: effects in overweight and obese 
subjects without diabetes mellitus.  Obesity (Silver Spring) 2014 Apr; 22(4):1042 -9.
De Nicola et al 2014
De Nicola L, Gabbai FB, Liberti ME, Sagliocca A, Conte G, Minutolo R.  Sodium/glucose cotransport er 
2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes.  Am J Kidney 
Dis.  2014; 64(1):16
-24.  
EASD 2016
Abstracts of 52nd EASD Annual Meeting.  Diabetologia; 2016 Aug. 59 Suppl 1:1 -581.
Eckart et al 2013
Eckardt KU ,Coresh J, Devuyst O, Johnson RJ, Köttgen A, Levey AS, et al. Evolving importance of 
kidney disease: from subspecialty to global health burden.  Lancet 2013 Jul 13;382( 9887).
EMA 2016
Guideline on clinical investigation of medicinal products 4 for the trea tment of chronic heart failure 
(draft), Committee for Medicinal Products for Human Use (CHMP).  EMA/CHMP/392958/2015.
Fioretto et al 2016
FiorettoP, Stefansson BV, Joh nsson E, Cain VA, Sjöström CD.  Dapagliflozin reduces albuminuria 
over 2 years in patien ts with type 2 diabetes mellitus and renal impairment.  Diabetologia 2016 Sep; 
59(9):2036 -9.
Gilbert RE 2016
Gilbert RE. SGLT2 inhibitors: β blockers forthe kidney?. Lancet Diabetes Endocrinol 2016 
Oct;4(10):814.  
Go et al 2004
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C -Y.  Chronic kidney disease and the risks of death, 
cardiovascular events, and hospitalisation.  N Engl J Me d 2004; 351:1296 -305.  
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
80 (98)Heerspink et al 2013
Heerspink H.  J.  L,Zeeuw, D, Wie L, Leslie B & List J.  Dapagliflozin a glucose -regulating drug with 
diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013 Sep;15(9):853- 62.  
Heerspin k et al 2016a
Heerspink HJ, Johnsson E, Gause- Nilsson I, Cain VA, Sjöström CD.  Dapagliflozin reduces 
albuminuria in patients with diabetes and hypertension receiving renin -angiotensin blockers.  Diabetes 
Obes Metab 2016 Jun;18(6):590 -7.  
Heerspink at al 2016b
Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ.  Sodium Glucose Cotransporter 2 
Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential 
Mecha nisms, and Clinical Applications.  Circulation 2016 Sep 6 ;134(10):752 -72.  
Kasichayanula et al 2014
Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW.  Clinical pharmacokinetics and 
pharmacodynamics of dapagliflozin , a selective inhibitor of sodium -glucose co -transporter type 2.  Clin 
Pharmacokinet .  2014 Jan;53(1):17 -27.  
Kohan et al 2014
Kohan DE, Fioretto P, Tang W and List JF.  Long -term study of patients with type 2 diabetes and 
moderate renal impairment shows that dapagliflozin educes weight and blood pressure but does not 
improve glycemic control .  Kidney International 2014; 85:962 –971.  
Kosiborod et al 2016
Kosiborod M, Xu J, Sjostrand M, Sjostrom CD.  Safety and Efficacy of Dapagliflozin in Combination 
with Potassium -sparing Agents.  American Diabetes Association; June 2016: New Orleans. Abstra ct 
1094- P.
Komala et al 2013
Koma la MG, Panchapakesan U, Pollock C, Mather A.  Sodium glucose cotransporter 2 and the diabetic 
kidney.  Curr Opin Nephrol Hypertens 2013, 22:113 –119.  
Korner et al 1994
Körner A, Eklöf AC, Celsi G,AperiaA.Increased Renal Metabolism in Diabetes Mechanism and 
Functional Implications.  Diabetes 1994 May;43(5):629 -33.
Levey at al 2009
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI et al. et al. A new equation 
to estimate glomerular filtration rate.  Ann I ntern Med  2009 May 5;150(9):604 -12.
Mudaliar et al 2016
Mudaliar S, Alloju S, Henry RR.  Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal 
Outcomes in the EMPA -REG OUTCOME Study? A Unifying Hypothesis.  Diabetes Care 2016 
Jul;39(7):1115 -22
.  
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
81 (98)Pollock et al 1991
Pollock CA, Field MJ, Bostrom TE, Dyne M, Gyory AZ, Cockyane DJH.  Proximal tubular cell sodium 
concentration in early diabetic nephropaty assessed by electron microprobe analysis.  Pflügers Arch 
1991; 418(1- 2):14 -17.
Rajasekeran et al 2016
Rajasekeran H, Lytvyn Y,Cherney DZI.  Sodium –glucose cotransporter 2 inhibition and cardiovascular 
risk reduction in patients with type 2 diabetes: the emerging role of natriuresis.  Kidney International 
2016; 89:524 –526.  
Sjöström et al 2015a
Sjöström  CD, Johansson P, Ptaszynska A, List J, Johnsson E. Dapagliflozin lowers blood pressure in 
hypertensive and non -hypertensive patients with type 2 diabetes.  Diab Vasc Dis Res .  2015 
Sep;12(5):352 -8.  
Sjöström et al 2015b
Sjostrom CD, Johansson P, Sug g J, Johnsson E.  Dapagliflozin reduces albuminuria on top of renin 
angiotensin system blockade in diabetic patients with moderate renal impairment.  ISN World Congress 
of Nephrology; March 2015; Cape Town. Abstract  SAT -461. 
Sjöström etal 2016
Sjöström CD, Greasley PJ, Xu J, Heerspink HJL.  Differential effects ofdapagliflozin oncardiovascular
riskfactors atvarying degreesofrenal function .  European Association for the Study of Diabetes 
(EASD), Sept 2016, Munich. Abstract 54.
Thomas 2014
Thomas MC.   Renal effects of dapagliflozin in patients with type 2 diabetes.  Ther Adv Endocrinol 
Metab 2014; 5(3):53- 61.  
Wanner et al 2016
Wanner C,Inzucchi SE,Lachin JM,Fitchett D,von Eynatten M, Mattheus M, et al; EMPA -REG 
OUTCOME Investigators. Empaglifloz in and Progression of Kidney Disease in Type 2 Diabetes . N 
Engl J Med. 2016 Jul 28;375(4): 323-34.
Yale et al 2013
Yale JF, Bakris G, Cariou B, Yue D, David -Neto E, Xi L et al.  Efficacy and safety of canagliflozin in 
subjects with type 2 diabetes and chron ic kidney disease.  Diabetes, Obesity and Metabolism 15: 463 –
473, 2013.
Zinman et al 2015
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al.  Empagliflozin, cardiovascular 
outcomes, and mortality in type 2 diabetes.  N Engl J Med 2015; 3 73:2117 -2128.  
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
82 (98)Appendix A Additional Safety Information
Further Guidance on the Definition of a Serious Adverse Event (SAE)
Life threatening
‘Life -threatening’ means that the patientwas at immediate risk of death from the AEas it 
occurred or it is suspected that use or continued use of the product would result in the subject ’s 
death.  ‘Life -threatening’ does not mean that had an AEoccurred in a more severe form it 
might have caused death (e.g., hepatit is that resolved wit hout hepatic failure).  
Hospitalisation
Outpati ent treatm ent in an emergency room is not in itself a serious AE , although the reasons 
for it may be (e.g., bronchospasm, laryngeal oedema).  Hospital admissio ns and/or surgical 
operati ons planned before or d uring a study are not considered AEs if the illness or disease 
existed before the patientwas enrolled in the study, provided that it did not deteriorate in an 
unexpected way  during the study .  
Important medical event or medical intervention
Medical and s cientific judgement should be exercised in deciding whether a case is serious in 
situations where important m edical events may  not be immediately life threatening or result in 
death, hospi talisat ion, disabili ty or incapaci ty but may jeopardize the patient or may  requi re 
medical intervention to prevent one or more outcomes listed in the definit ion of serious.  These 
shoul d usually be considered as serious.  
Simply stopping the suspect drug does not mean that it is an important medical event; medical 
judgeme nt must be used.  
 Angioedema not severe enough to require intubation but requiring iv 
hydrocortisone treatment
 Hepatotoxicit y caused by paracetamo l (acetaminophen) overdose requiring 
treatm ent wi th N-acetylcysteine
 Intensive treatment in an emergency room or at home for allergic 
bronchospasm
 Blood dy scrasias (e.g., neutropenia or anaemia requi ring bl ood transfusi on, 
etc.) or convulsio ns that do not result in hospitalisation
 Development of drug dependency or drug abuse
A Guide to Interpreting the Causality Question
When making an assessment of causalit y consi der the fo llowing factors when deciding if there 
is a ‘reasonable possibilit y’that an AE m ay have been caused by the drug.  
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 Mar ch 2020
83 (98) Time Course.  Exposure to suspect drug.  Has the patient actually received 
the suspect drug?  Did the AE occur in a reasonable temporal relat ionship 
to the administration of the suspect drug?
 Consistency wit h known drug profile.  Was the AE consistent with the 
previous knowledge of the suspect drug (pharmacology and toxico logy) or 
drugs of the same pharmacological class? Or could the AE be ant icipated 
from its pharm acological properti es?
 De-challenge experience.  Di d the AE resolve or improve on stopping or 
reducing the dose of the suspect drug?
 No al ternative cause.  The AE cannot be reasonably explained by another
aetiologysuch as the underlying disease, other drugs, other host or 
environmental factors.  
 Re-challenge experi ence.  Di d the AE reoccur if the suspected drug was 
reintroduced after having been stopped? AZ would not nor mally 
recommend or support a re-challenge .  
 Laboratory  tests.  A specific laboratory  invest igation (if performed) has 
confirmed the relat ionship .  
In difficult cases, other factors could be considered such as:
 Is this a recogni zedfeature of overdose of the drug?
 Is there a known mechanism?
Causalit y of ‘related’ is m ade if fo llowing a review of the relevant data, there is evidence for a 
‘reasonable possibilit y’of a causal relationship for the individual case.  The expressio n 
‘reasonable possibilit y’ of acausal relationship is meant to convey, in general, that there are 
facts (evidence) or arguments to suggest a causal relat ionship.  
The causalit y assessment i s perform ed based on the available data including enough 
inform ation to m ake an informed judgme nt.  With limited or insufficient information in the 
case, i t is likely  that the event(s) will be assessed as ‘not related’.  
Causal relat ionship in cases where the disease under study  has deteri orated due to l ack of effect 
shoul d be classified as no reas onable possibilit y.  
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
84 (98)Appendix B International Airline Transportation Association (IATA) 6.2 
Guidance Document
Labelling and shipment of biohazard samples
International Airline Transportation Associat ion (IATA) classifies bi ohazardous agents into 
3categori es.  For transport purposes the classificatio n of infect ious substances according to risk 
groups was removed from the Dangerous Goods Regulat ions (DGR) in the 46thedition (2005).  
Infectious substances are now classified e ither as Category  A, Category  B or Exem pt.  There i s 
no di rect rel ationship between Risk Groups and categories A and B.  
Category A Infectious Substances are infect ious substances in a form that, when exposure to 
it occurs, i s capable of causing permanent disabilit y, life-threatening or fatal  disease in 
otherwi se healt hy humans or animals.  Category  A pathogens are e.g., Ebola, Lassa fever virus:
 Are to be packed and shipped in accordance wit h IATA Instruction 602 
Category B Infectious Substances are infe ctious Substances that do not meet the criteria for 
inclusio n in Category  A.  Category  B pathogens are e.g., Hepatit is A, B, C, D, and E viruses, 
Hum an immunodeficiency virus (HIV) ty pes1 and 2.  They  are assigned the following UN 
number and proper shippi ng name:
 UN 3373 –Biological Substance, Category  B
 Are to be packed in accordance with UN3373 and IATA 650
Exempt -all other materials wit h minimal risk of containing pathogens
 Clinical trial samples will fall into Category  B or exempt under IATA 
regul ations.
 Clinical trial samples will routinely be packed and transported at ambient 
temperature in IATA 650 com pliant packaging.
 Biological samples transported in dry  ice requi re addi tional dangerous 
goods specification for the dry -ice content.
 IATA co mpliant courier and packaging materials should be used for 
packing and transportation and packing should be done by  an IATA 
certified person, as applicable.
 Samples routinely transported by  road or rail are subject to local 
regul ations which require that they  arealso packed and transported in a 
safe and appropriate way  to contain any  risk of infecti on or contaminat ion 
by using approved couriers and packaging / containment materials at all 
times.  The IATA 650 bio logical sample containment standards are 
encouraged wherever possible when road or rail transport is used.  
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
85 (98)Appendix C New York Heart Association (NYHA) Functional 
Classification
NYHA Functional Classification
Class Patient symptoms
I No limitation of physical activity.  Ordinary 
physical activity does not cause undue fatigue, 
palpitation, dyspnoea (shortness of breath).  
II Slight limitation of physical activity.  
Comfortable at rest.  Ordinary physical activity 
results in fatigue, palpitation, dyspnoea (shortness 
of br eath) .  
III Marked limitation of physical activity.  
Comfortable at rest.  Less than ordinary activity 
causes fatigue, palpitation, or dyspnoea.  
IV Unable to carry on any physical activity without 
discomfort.  Symptoms of heart failure at rest.  If 
any physical activity is undertaken, discomfort 
increases .  
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
KDQ OL-36_v1_ 2000_Orig_WS_ Paper_English-US_11O ct2016_D000 0C00000StudyNumber: SiteNumber:
SubjectNumber:E__ _ _ _ _ _ VisitNumber: AssessmentDate:
Your Health
Thissurvey includes a widevarietyof qu estions about your health and your 
life.Weareinterested inhow youfeelabout each ofthese issues.
1. In gen eral,wouldyousayyour health is:[Mark an                                                                 intheoneboxthat 
bestdescribes your answer.]
Excellent Verygood Good Fair Poor

                       1
                         2
                      3
                        4
                         5
The following itemsareabout activities youmight doduring a typ icalday. 
Does your health now limit youintheseactivities?Ifso,how much?
[Mark an inaboxoneach line.]
Yes, 
limiteda 
lotYes, 
limiteda 
littleNo,not 
limitedat 
all
2.Moderate activitie s,such as m oving atable, 
pushin g avacuum cl eaner, bowling ,or
playing golf.............. ................... .............. . 1........... . 2........... . 3
3.Climbing several flights ofstairs ............... . 1........... . 2........... . 3
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
KDQ OL-36_v1_ 2000_Orig_WS_ Paper_English-US_11O ct2016_D000 0C00000StudyNumber: SiteNumber:
SubjectNumber:E__ _ _ _ _ _ VisitNumber: AssessmentDate:
Duringthepast 4week s,have you had anyofthefollowingprobl emswith 
yourwork orother regular daily activ itiesasaresultofyour physi calhealth?
Yes No
 
4.Accom
plish edlessthan youwould like ............... 1......... ... 2
5.    We relimitedinthekind ofwork or other
activities .................. .. ........................................... 1........... . 2
Duringthepast 4week s,have you had anyofthefollowingprobl emswith 
yourwork orother regular dailyactivitiesas a resultofanyemotional 
proble ms(such asfeeling depressedoranxious)?
Yes No
 
6.Ac
comp lishedlessthan you would like .............. . 1........... . 2
     7.    Didn’t do work or otheractiviti es as carefully
asusual............................. ................... ................ . 1........... . 2
8.Duringthepast 4weeks, how muchdidpain interfere with your
normal work (including bothworkoutside thehomeand
housework)?
Notatall Alittle bit Moderat ely Quite abit Extremely
    
1                                          2                                      3                                   4                                        5
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
KDQ OL-36_v1_ 2000_Orig_WS_ Paper_English-US_11O ct2016_D000 0C00000StudyNumber: SiteNumber:
SubjectNumber:E__ _ _ _ _ _ VisitNumber: AssessmentDate:
Thesequestions areabou thow you fee l andhow thingshave beenwith you 
during the past 4week s.For each ques tion, please give theone ans werthat 
comes closesttotheway youhave beenfeeling.
How mu chofthetime duringthepast 4weeks…
Allofthe 
timeMost of 
thetimeA good bit 
of the timeSome of t he 
t imeAlittle 
ofthe 
timeNone 
of
the
time
     
9.Haveyou feltcalm 
andpeaceful? ...........              1...........         2 ........ ....         3 ...............       4............         5..... 6
10.Didyou havealot
ofenerg y?...............              1...........         2 ........ ....         3 ...............        4............         5 ..... 6
11.Haveyoufelt 
downhe artedand 
blue? ........ ................              1...........         2 ........ ....         3 ...............        4............         5 ..... 6
12. Duringthe past 4 weeks, how much of thetime hasyour physicalhealth or
emotional problems interfered w ith your social activities(like visit ingwith 
friends, relat ives, etc.)?
All
ofthetimeMost
ofthetimeSome
ofthetimeAlittle
ofthetimeNone
ofthetime
    
                         1 2 3 4 5
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
KDQ OL-36_v1_ 2000_Orig_WS_ Paper_English-US_11O ct2016_D000 0C00000StudyNumber: SiteNumber:
SubjectNumber:E__ _ _ _ _ _ VisitNumber: AssessmentDate:
Your Kidney Disease
How true orfalseiseach of the following statements foryou?
Definitely 
trueMostly 
trueDon’ t 
knowMostly 
falseDefinitely  
false
    
13.Mykidneydisea se 
interferes too much 
with my life ...........                             1 ...........             2............                3............               4...........              5
14.Too much of my 
time isspent 
dealing with my
kidney disease .......                            1 ............            2............                3...........                4...........              5
15.I feelfrustrated 
dealing with my 
kidney disease .......                            1 ............            2............               3............               4...........              5
16.I feellike a burden 
on my fa mily.........                             1 ............            2............                3...........               4...........              5
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
KDQ OL-36_v1_ 2000_Orig_WS_ Paper_English-US_11O ct2016_D000 0C00000StudyNumber: SiteNumber:
SubjectNumber:E__ _ _ _ _ _ VisitNumber: AssessmentDate:
Duringthepast4weeks, towhat extentwere youboth eredbyeachofthe 
following?
Not 
bother edSomewhat
botheredModerately
bother edVery  much
botheredExtremely
bothered
    
17.Soreness in your muscles?
................                1..............        2............ .....        3...............        4............... .      5
18.Chestpain?............                 1…........... 2…........ ..... 3............... 4........... ..... 5
19.Cramps? ................ 1.............. 2................. 3............... 4........... ..... 5
20.Itchyskin? ............. 1.............. 2................. 3............... 4........... ..... 5
21.Dryskin? ............... 1.............. 2................. 3............... 4........... ..... 5
22.Shor tnessof
breath? ................... 1.............. 2................. 3............... 4........... ..... 5
23.Faintness or 
dizzines s?.............. 1.............. 2................. 3............... 4........... ..... 5
24.Lack ofappetite? ... 1.............. 2................. 3............... 4........... ..... 5
25.Washed outor 
drain ed?................. 1.............. 2................. 3............... 4........... ..... 5
26.Numbness inhands or
feet? .................. 1.............. 2................. 3............... 4........... ..... 5
27.Nausea or upset stom ach?
................ 1.............. 2................. 3............... 4........... ..... 5
28a.(Hemodialy sis patient 
only) Problems with y our 
acces s site? ............1.............. 2................. 3............... 4........... ..... 5
28b.(Peritoneal dialy sis patient 
only) Problems with y our
catheter site?..........1.............. 2................. 3............... 4........... ..... 5
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
KDQ OL-36_v1_ 2000_Orig_WS_ Paper_English-US_11O ct2016_D000 0C00000StudyNumber: SiteNumber:
SubjectNumber:E__ _ _ _ _ _ VisitNumber: AssessmentDate:
Effects ofKidney Disease onYour Daily Life
Somepeoplearebothered bytheeffects of ki dney diseaseon th eirdaily life,
whileothersarenot.How mu chdoes kidney disease bother youin each ofthe
followi ngareas?
NotatallSomewh atModerate lyVery muchExtre mely
bother ed bother ed bothered bothered bothered
    
29.Fluid restric tion? ... 1.............. 2................ 3................ 4........... .... 5
30.Dietary
restric tion? ............ 1.............. 2................ 3................ 4........... .... 5
31.Your ability to
work aroundthe
house? 1.............. 2................ 3................ 4........... .... 5
32.Your ability to 
travel? 1.............. 2................ 3................ 4........... .... 5
33.Being depe ndent
on doctors and
other medica lstaff 1.............. 2................ 3................ 4........... .... 5
34.Stress orworries 
caused bykidney 
disease? 1.............. 2................ 3................ 4........... .... 5
35.Your sexlife? ........ 1.............. 2................ 3................ 4........... .... 5
36.Yourpersonal 
appearance? 1.............. 2................ 3................ 4........... .... 5
Thank you forcompleting these questions!
Clinical Stu dy Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
KDQ OL-36_v1_ 2000_Orig_WS_ Paper_English-US_11O ct2016_D000 0C00000D2 EuroQol five -dimensional five -level questionnaire (EQ -5D-5L
HealthQuestionnaire
Englishversionfor theUK
UK(English)©2009EuroQ olGroup EQ-5D™isatrademark of the EuroQolGroupClinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
Under eachheading,pleasetick the ONE box th atbest descri besyour health TODAY.
MOBILITY
Ihave noproble msinwalkingabou t                                                 
Ihave slight problemsinwalkingabout                                            
Ihave mo derateproblems inwalking a bout                                     
Ihave seve reproblems inwalking about                                          
Iam un abletowalk about                                                                  
SELF-CARE
Ihave no pr oblemswashingordressingmyself                                
Ihave slightprobl emswashing or dr essing myse lf                          
Ihave mo derateproblems washing ordressing myself                   
Ihave seve reproblems was hing or dressingmyself                        
Iam una bletowash or dress myse lf                                                 
USUALACTIVITIES (e.g. work,study,housework, familyor 
leisure activities)
Ihave noproble msdoingmyusualactivities                                   
Ihave slight problemsdoingmyusualactivities                               
Ihave mo derateproblems doingmyusual acti vities                        
Ihave seve reproblems doingmyusual activities                            
Iam un abletodomyusual activities                                                
PAIN /DISCOMFORT
Ihave no pa inordiscomfort                                                              
Ihave slight pain ordiscom fort                                                          
Ihave mo deratepainordiscomfort                                                   
Ihave severe pain ordiscom fort                                                       
Ihave extreme pain or discomfort                                                     
ANXIETY/DEPRESSION
Iamnotanxiousor depressed                                                          
Iamslightlyanxio us or depressed                                                    
Iammoderatelyanxious ordepress ed                                             
Iamseve relyanxious or depressed                                                  
Iamextrem elyanxious or de pressed                                               
UK(English)©2009EuroQ olGroup EQ-5D™isatrademark of the EuroQolGroupClinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
•We would like to know how good or bad your health is TODAY.
•This scale isnumberedfrom 0to100.
•100meansthebesthealth you can imagine.
0meansthe w orsthealthyou can imagine.
•MarkanX on thescale to in dicat ehow your he althisTODAY.
•Now, please wr itethenumberyoumarke d on the sca leinthebox 
below.

Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
96(98)Appendix E Genetic Research
Rationale and Objectives
AstraZeneca intends to collect and store DNA for genet ic research to explore how genetic 
variat ions may affect clinical parameters, risk and prognosis o fdiseases, and the response to 
medicat ions.  Genetic research may lead to better under standing of diseases, better diagnosis 
of diseases or other improvements in healt h care and to the discovery of new di agnostics, 
treatm ents or m edicat ions.
In addit ion, collect ion of DNA samples from populat ions wit h well described clinical 
characterist icsmay lead to improvements in the design and interpretation of clinical trials and, 
possibl y, to geneti callyguided treatm ent strategies.
Genetic Research Plan and Procedures 
Selection of genetic research population
Study selection record
All subjects wil l be asked to participate in this genetic research.  Participat ion is vo luntaryand 
if a subject declines to participate there will be no penalt yor loss of benefit.  The subject will 
not be excluded from a ny aspect of the m ain study .
Inclusion criteria
For inclusio n in this genet ic research, subjects must fulfil all o f the inclusio n criteria described 
in sect ion 3.1 of the main body of the Clinical Study Protocol  and:
 Provi de inform ed consent for the genetic sampling and analy ses.
Exclusion criteria
Exclusio n from this genet ic research may beforanyof the excl usion criteria specified in 
section 3.2 of the Clinica lStud yProtocol  orany of the fo llowing:
 Previous allogeneic bone marrow transplant
 Non-leukoc yte depleted whole blood transfusion in 120 da ys of genetic 
sample collect ion
Discontinuation of subjec ts from this genetic research
Specific reasons for discont inuing a subject from this genet ic research ar e:
Withdrawal o f consent for genet ic research: Subjects maywithdraw from  this genet ic 
research at a ny time, independent of a ny decisi on concerning parti cipat ion in other aspects of 
the main stud y.  Vol untary discontinuat ion will not prejudice further trea tment.  Procedures 
for discont inuat ion are outlined in Sect ion 5.6 of the main Clinical Study Protoco l.
Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 March 2020
97(98)Collection of samples for genetic research
The blood sample for genet ic research will be obtained fro m thesubjects atVisit 2 at
rando misat ion.  Although DNA is stable, ear ly sample co llection is preferred to avoi d 
introducing bias through excluding subjects whomaywithdraw due to an adverse event (AE), 
such subjects would be important to include in any genet icanalysis. If for any reason the 
sample i s not drawn at Visit2, it maybe taken at any visit until  the last study visit. Only one 
sample should be co llected per subject for genet ics during the stud y.  Sam ples will be 
collected, labelled, stored and shipped as detailed in the Laboratory Manual.
Coding and storage of DNA samples
The processes adopted for the coding and storage of samples for genet ic anal ysis are important 
to maintain subject confidentiali ty.  Sam ples will be stored for a maximum o f 15 ye ars, from  
the date of last subject last visi t, after which they will be destro yed.  DNA is a finite resource 
that is used up during ana lyses.  Sam ples will be stored and used unt il no further ana lyses are 
possible or the maximum storage time has been reached.
An addit ional second code will be assign ed to the bl ood sam ple ei ther before or at the time of 
DNA extraction replacing the informat ion on the sample tube.  Thereafter, the sample will be 
ident ifiable by the second, unique number onl y.  This number i s used to i dentifythe sample 
andcorresponding data at the AstraZeneca genet ics laboratori es, or at the designated 
organi zation. No personal details ident ifying the individual will be available to any person 
(AstraZeneca empl oyee ordesignated organi zations working wi th the DNA).
The link between thesubject enrolment /randomisation code and the second number will be 
maintained and stored in a secure environment, with restricted access at AstraZeneca or 
designated organizat ions.  The link will be used to ident ifythe relevant DNA samples for 
analysis, facilitate correlat ion of genot ypic resul ts wi th clinical  data, all ow regulatory audit 
and to trace samples for destruction in the case of withdrawal o f consent.
Ethical and Regulatory Requirements
The principles for ethical and regulatory requi rements for the study, including this genet ics 
research component, are outlined in Sect ion 10 of the main Clinical Study Protocol.
Informed consent
The genetic component of this study is optional and the subject mayparticipate in other 
components of the m ainstudy without participat ing in the genet ic component.  To participate 
in the genet ic co mponent of the study the subject must si gn and date both the consent form for 
the main study and the genet ic co mponent of the stud y.  Copi es of both si gned and dated 
consent fo rms m ust be given to the subject and the original filed at the study centre .  The 
Principal Investigator(s) is responsible for ensuring that consent is given free lyandthatthe 
subject understands that they mayfreely discont inue fro m the genet ic aspect o f the study at 
anytime.
Subject data protection
AstraZeneca will not provide individual geno type resul ts to subjects, anyinsurance compan y, 
anyempl oyer, thei r family members, general physician unless requi red to do so by law.
Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169AC00001
Version 4.0
Date 17 Mar ch 2020
98(98)Extra precautions are taken to preserve confident ialityand prevent genetic data being linked to 
the identi tyof the subject. In except ional circumstances, however, certain individuals might 
see both the genetic data and the personal ident ifiers of a subject. Forexampl e, in the case of 
a medical emergency , an AstraZeneca P hysician or an investigator might know a subject’s 
ident ityand also have access to his or her genetic data.  Also Regulatory authori ties may  
requi re access to the relevant files, though the subject’s medical inf ormation and the genet ic 
files woul d rem ain p hysicallyseparate.
Data management
Anygenot ype data generated in this study will be stored at a secure system  at AstraZeneca 
and/or designated organizations to analysethe sampl es.
The results from this genet ic research may be reported in a separate report fro m the CSR or 
published in scient ific journals.
AstraZeneca and its designated organisat ionsmay share summary resul ts (such as genet ic 
differences fro m groups of individuals with a disease) from this genet ic research wit h other 
researchers, such as Hospitals, Academic Organizati on or Heal th Insurance Co mpanies. This 
can be done byplacing the results in scient ific databases, where theycan be combined wit h 
the resul ts of similar studies to learn even more a bout healt h and disease. The researchers can 
onlyuse thi s informat ion for health related research purposes. Researchers may seesummary  
resul ts but they will not be able to see individual subject data or a nypersonal ident ifiers.
Some or all  ofthe clinic al datasets from  the m ain study maybe m erged wi th the genet ic data 
in a suitable secure environment separate from the clinical database.
Statistical Methods and Determination of Sample Size
The number of subjects that will agree to participate in the gene tic research is unknown.  Itis 
therefore not possible to establish whether sufficient data will be collected to allow a formal 
statist ical evaluat ion or whether onl y descri ptive statist ics will be generated.  A Statistical 
Analysis Plan will be prepared w here appropriate.
SIGNATURE PAGE
This is a representation of an electronic record that was signed
electronically and this page is the manifestation of the electronic signature
Document Name: d169ac00001-csp-v4
Document Title: D169AC00001 Clinical Study Protocol version 4
Document ID: Doc ID-003216276
Version Label: 5.0 CURRENT LATEST APPROVED
Server Date
(dd-MMM-yyyy HH:mm ‘UTC’Z)Signed by Meaning of Signature
20-Mar-2020 09:28 UTC Content Approval
19-Mar-2020 15:38 UTC Content Approval
19-Mar-2020 15:12 UTC Content Approval
19-Mar-2020 15:19 UTC Content Approval
Notes: (1) Document details as stored in ANGEL, an AstraZeneca document management system.
